



Government of Pakistan  
Ministry of National Health Services, Regulations & Coordination  
Drug Regulatory Authority Of Pakistan  
Health & OTC Products Division (Non-Drugs)  
\*\*\*\*\*

Islamabad, the 02<sup>nd</sup> August, 2021

“SAY NO TO CORRUPTION”

**Subject: Submission of deficient information / documents**

The applications of following applicants were placed before the Enlistment Evaluation Committee (EEC) in its 87<sup>th</sup> meeting held on 24<sup>th</sup> March, 2021 and the same have been deferred being deficient of the information / documents as specified in column (3) of the Table below which may be furnished within 20 days of uploading of this letter on official website of DRAP along with soft data as per **Annexed Format** at the end of this letter/document. Replies received after given time will not be entertained:-

S.No	Brand name	Decision
(1)	(2)	(3)
<b>M/s Alaq Laboratories, 5-Main Road, Amir Town, Lahore (E. No. 0089)</b>		
1.	Al-Riyan Cinnamon & Clove Capsules	Deferred for Justification of use of 2 capsule per serving dose
2.	Al-Riyan dandelion capsule	Deferred for submission of Monograph of Dandelion extract.
3.	Al-Riyan Ginger & Garlic Capsules	Deferred for Justification of use of 2 capsule per serving dose
4.	Al-Riyan Green Tea Capsules	Deferred for Justification of use of 2 capsule per serving dose
5.	Al-Riyan Goji Berry capsules	Deferred for submission of Monograph of goji berry extract
<b>M/s Arber Pharma, Plot No. 626-Sunder Industrial Estate, Lahore (E. No. 00327)</b>		
6.	Essential Palace Black Seed Softgel Capsules	Deferred for Justification of use of 2 capsule per serving dose
7.	Essential Palace Calcium Care Softgel Capsules	Deferred for Justification of use of 2 capsule per serving dose
8.	Essential Palace Fish Oil Softgel Capsules	Deferred for Justification of use of 2 capsule per serving dose
9.	Essential Palace Libido Booster Softgel Capsules	Deferred for Justification of use of 2 capsule per serving dose and change of brand name.
10.	Essential Palace Male Super Enhancement Softgel Capsules	Deferred for Justification of use of 2 capsule per serving dose
11.	Essential Palace Royal Jelly and Red Ginseng Softgel Capsules	Deferred for Justification of use of 2 capsule per serving dose
12.	Essential Palace Salvia Extract Softgel Capsules	Deferred for Justification of use of 2 capsule per serving dose
13.	Essential Palace Shilajit Softgel Capsules	Deferred for Justification of use of 2 capsule per serving dose and monograph of yohimbe extract.
14.	Essential Palace Wild Female Softgel Capsules	Deferred for Justification of use of 2 capsule per serving dose and change of brand name.
<b>M/s Haven Pharmaceuticals Pvt. Ltd., Plot No. 65-A, M-3, Industrial Estate, Sahianwala, Faisalabad (E. No. 00985)</b>		
15.	Apitaz Syrup	Deferred for submission of Monographs of Cichorium Intybus extract, Caparis spinosa extract, Emblica Officinalis extract, Tinospora Cordifolia extract, Achillea Millefolium extract, Tamarix gallica extract, Elettaria Cardamomum extract, Boerhavia Diffusa extract
16.	Fertile-F Capsules	Deferred for submission of signed and stamped form 3.
17.	Superm-M Tablet	Deferred for submission of Monograph of horny goat weed extract
18.	Surevant Syrup	Deferred for submission of Monograph of calcium lactate gluconate
19.	Tribone capsules	Deferred till finalization of common molecules list.
<b>M/s Paramount HealthCare, 36-Industrial Triangle, Kahuta Road, Islamabad (E. No. 00395)</b>		

*(Signature)*

S.No	Brand name	Decision
(1)	(2)	(3)
20.	Fastak Plus 0.075% Cream	Deferred till finalization of common molecules list.
21.	Fastak Cream	Deferred till finalization of common molecules list.
22.	New Mood Capsule (300mg)	Deferred for submission of Monograph of Hypericum perforatum extract
<b>M/s Oasis Pharma, 23-Km Raiwind Road, Lahore (E. No. 00779)</b>		
23.	Magnovit Powder	Deferred for Availability of food supplement section
<b>M/s. Qarshi Industries (Pvt.) Ltd., (E. No. 000414) Plot NO.56/1-4, 82, 82/1, 82/1-A, &amp; 83, Phase 1 &amp; II, Industrial Estate Hattar, District Haripur</b>		
24.	Qarshi's SulfoylKARE Capsule	Deferred for clarification of Sulphure substituted pilve oil and provision of monograph and COA
25.	Qarshi's KasniKARE Capsule	Deferred for provision of monograph of epidium Sativu Sp
26.	Qarshi's UtremKARE Capsule	Deferred for provision of monograph of Dactylorhiza Incarnate and Agate Compound. Wrong name of active ingredient
27.	Qarshi's StyekARE Capsule	Deferred for provision of Senna Insularis monograph
28.	Qarshi's FewmigKARE Capsule	Deferred for provision of Monograph of Magnesium Compound (Citrate) (S.P) 245mg TanacetumParthenium Ext.
29.	Qarshi's FauladKARE Tablet	Deferred for clarification of Active ingredient name in UPI /API/HP
30.	Qarshi's Obesigone Capsule	Deferred for clarification of the ingredients being used
<b>M/s Bless Laboratories (Pvt.) Ltd. (E. No. 0063) Factory No.179, 1.5-KM, Kattar Band Road, Off Multan Road, Thokar Niaz Baig, Lahore</b>		
31.	Bolt Soft gelatin capsule	Deferred for provision of monograph of extracts of the ingredients
32.	B Sun 10 capsules	Deferred for clarification for stability of Vitamin-D in hard gelatin capsule
33.	Bless's Branova X Tablet	Deferred for provision of Monograph and COA of Alpha GPC not given and strength of Alpha GPC is above 192mg which is high then recommended
34.	Vita miner tablet	Deferred for provision of Testing methods of Extracts of Rosa centifolia and Withaniasomnifera
35.	Tribufer capsule	Deferred for provision of Monograph od extracts of Tribulus terrestris , Epimedium and Withania somnifera is required
<b>M/S Ervas Neutrabiotics, 1-Km G.T Road,Jehangira,Swabi, KPK-Pakistan. (E. No. 001131)</b>		
36.	ERVAS's Digest-L Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Convert strength of active ingredient from 750IU per serving to IU per ml.</li> <li>The applied formulation contains Lactase which is added in the list of common molecules.</li> <li>Stability undertaking is missing.</li> </ul>
37.	ERVAS's Liverx Syrup	EEC decided to defer the application for enlistment to seek clarification since the firm applied same formulation with brand name "Live-B Syrup".
38.	ERVAS's Live-B Syrup	EEC decided to defer the application for enlistment to seek clarification since the firm applied same formulation with brand name "Liverx Syrup".
39.	ERVAS's KID-REST DROPS	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Provide monograph of all ingredients in extract form.</li> <li>Brand name needs to be changed.</li> </ul>
40.	ERVAS's NEURORAPID SYRUP	EEC decided to defer the application for enlistment for the change of brand name.
41.	ERVAS's MALEX Sachets	EEC decided to defer the application for enlistment for the provision of monograph and CoA of Tongkat Ali Root Extract.
<b>M/s S. Asia Oriental Pharma, Mosa Dhok Ghulam Ali, P.O Sagari, Rawalpindi (E. No. 00354)</b>		
42.	FIBRO LINK (VET) Oral Liquid	EEC decided to defer the application for enlistment due to following reacons:



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Notarized undertaking regarding brand name resemblance is missing.</li> <li>Submission of stability data undertaking on company letter head is missing.</li> </ul>
43.	COUGH CURE (VET) Oral Liquid	EEC Decided to defer the application for enlistment for the change of brand name.
44.	GROW UP(VET) ORAL LIQUID	<ul style="list-style-type: none"> <li>EEC Decided to defer the application for enlistment for the change of brand name.</li> </ul>
45.	GYNO LINK (VET) Oral Powder	EEC Decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Provide monograph of all ingredients and submit revise form-3 w.r.t specification of each ingredient as per monograph.</li> </ul>
46.	BONE LINK (VET) Oral Powder	EEC Decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>The applied formulation is in duplication with SA DCP (VET) Oral Powder.</li> <li>Justify the applied formulation as alternative herbal medicine keeping in view the origin of active ingredient.</li> </ul>
47.	CENTA LINK (VET) Oral Powder	EEC Decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Provide monograph of all ingredients and submit revise form-3 w.r.t specification of each ingredient as per monograph.</li> </ul>
48.	SA STOMACH(VET) Oral Powder	EEC Decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Provide monograph of all ingredients.</li> <li>Revise form-3 w.r.t. name and specification of each ingredient as per monograph.</li> </ul>
49.	SA HEAT(VET) Oral Powder	EEC Decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed.</li> <li>Provide monograph of Polygonum viviparum and Randia Dumetrum.</li> <li>Revise form-3 w.r.t. specification of each ingredient as per monograph.</li> </ul>
50.	SA DCP (VET) Oral Powder	Deferred EEC Decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>The applied formulation is in duplication with Bone Link (Vet) Oral Powder.</li> <li>Justify the applied formulation as alternative herbal medicine keeping in view the origin of active ingredient.</li> </ul>
51.	SA JAIR (VET) Oral Powder	EEC Decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Provide monographs of all ingredients.</li> <li>Revise form-3 w.r.t. specification of each ingredient as per monograph.</li> </ul>
52.	GEST LINK (VET) Oral Powder	EEC Decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>The applied formulation contains Colocynth and Nux vomica which are toxic plants, submit clarification regarding safety of applied formulation.</li> <li>Provide monograph of all ingredient.</li> </ul>
53.	AJ GOO-Pain (VET) Oral Powder	EEC Decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed.</li> <li>Provide monographs of all ingredients.</li> <li>Revise form-3 w.r.t. specification of each ingredient as per monograph.</li> <li>Notarized undertaking regarding brand name resemblance is missing</li> <li>Submission of stability data undertaking on company letter head is missing.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>The firm applied similar formulation with insignificant difference with brand name AJ GO-Pain (VET) Oral Powder.</li> </ul>
54.	AJ GO-Pain (VET) Oral Powder	<p>EEC Decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Brand name needs to be changed.</li> <li>Provide monographs of all ingredients.</li> <li>Revise form-3 w.r.t. specification of each ingredient as per monograph.</li> <li>The firm applied similar formulation with insignificant difference with brand name AJ GOO-Pain (VET) Oral Powder.</li> </ul>
55.	Energic Plus (Vet) Oral Powder	<p>EEC Decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide monographs of specific salts of all ingredients.</li> <li>Revise form-3 w.r.t. names and specification of each ingredient as per monograph.</li> <li>Notarized undertaking regarding brand name resemblance is missing.</li> <li>Submission of stability data undertaking on company letter head is missing.</li> </ul>
56.	Milko Link (Vet) Oral Powder	<p>EEC Decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Brand name needs to be changed.</li> <li>Provide monographs of specific salts of all ingredients.</li> <li>Revise form-3 w.r.t. names and specification of each ingredient as per monograph.</li> <li>Notarized undertaking regarding brand name resemblance is missing</li> <li>Submission of stability data undertaking on company letter head is missing.</li> </ul>
<b>M/s MS Laboratories, St.No.28, Nisar Colony Industrial Area, Samanabad, Faisalabad. (E. No. 00551)</b>		
57.	MS EASY BREATH TABLETS	EEC decided to defer the application for enlistment for the provision of evidence that the source of <i>Blatta orientalis</i> is free from TSE/BSE.
58.	MS ANTI-ALLERGIC SYRUP	EEC decided to defer the application for enlistment for the change of brand name.
59.	MS ASHOKA CORDIAL SYRUP	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide alternate brand names.</li> <li>Provide evidence that the source of <i>sepia officinalis</i> is free from TSE/BSE.</li> </ul>
60.	MS BLATTA SYRUP	<ul style="list-style-type: none"> <li>EEC decided to defer the application for enlistment for the provision of evidence that the source of <i>Blatta orientalis</i> is free from TSE/BSE.</li> </ul>
61.	MS KIDNEX SYRUP	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Brand name needs to be changed.</li> <li>Provide evidence that the source of <i>Cantharis vesicatoria</i> is free from TSE/BSE.</li> </ul>
<b>M/s Allegro MH Labs 25-Km Main Canal Road, Near Rizwan Garden, Manawan, Lahore (E. No. 001162)</b>		
62.	PIPJEL SUSPENSION	<p>EEC decided to defer the application for enlistment on following grounds:</p> <ul style="list-style-type: none"> <li>The applied formulation contains toxic plant i.e. <i>Ocimum basillicum</i> needs clarification regarding safety of ingredient in applied dose.</li> </ul>
63.	PREZYM SYRUP	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide monograph of “<i>Medicago sativa</i>” being used as herbal active ingredient.</li> </ul>
<b>M/s AMFAHH Pharma,</b>		



S.No	Brand name	Decision
(1)	(2)	(3)
<b>Khewat No.1679, Khatauni No.2591, Khasra No. 2347-2348, 18-Km Multan Road, Lahore. (E. No. 01152)</b>		
64.	Pro-Gest Suppository	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Provide monograph of Wild Yam Extract.</li> </ul>
65.	Atrophy Clear Suppository	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Provide monograph and COA of Calendula Officinalis oil.</li> <li>• Provide safety undertaking of the applied formulation on notarized stamp paper duly signed by the owner of the firm.</li> </ul>
66.	BV Care Suppository	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Justify the use of applied formulation as health product as per SRO 412(I)/2014 as applied formulation comprises of single active ingredient i.e. Borax.</li> </ul>
67.	P Away Suppository	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Provide monograph and COA of Butchers Broom Extract.</li> <li>• Provide safety undertaking of the applied formulation on notarized stamp paper duly signed by the owner of the firm.</li> </ul>
68.	ALNAENAE Tablets	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Justify the use of same active ingredient twice in single formulation.</li> <li>• Form-3 needs to be revised w.r.t. mentioning the exact form (Extract /Oil) being used in the formulation as per monograph.</li> </ul>
69.	Buspan Compound Plus Tablets	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> <li>• Provide monograph of all ingredients in their extract/oil form.</li> <li>• Form-3 needs to be revised w.r.t mentioning the names of ingredients as per monograph.</li> </ul>
70.	Chymrel Tablets	EEC decided to defer the application for enlistment since the applied formulation contains enzymes which are added in the list of common molecules.
71.	Scab Off Lotion	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> <li>• Provide monograph of Chrysanthemum extract.</li> </ul>
72.	Wntrgreen Cream	EEC decided to defer the application for enlistment for the change for brand name.
73.	Mos Go Lotion	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>• Convert strength from percentage to ml per ml of lotion.</li> <li>• Provide monograph of citronella oil</li> </ul>
74.	Dolyfax ointment	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Convert strengths from percentage to mg per gram or ml per gram of formulation. Form-3 needs to be revised w.r.t. mentioning the names and specification of ingredient as per monograph.</li> <li>• Provide monograph of Calendula officinalis and thuja occidentalis in extract/oil form.</li> </ul>
75.	Variway Cream	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Provide monograph of all ingredients and revise form-3 w.r.t. names and specification as per monograph.</li> </ul>
76.	Easy Way Cream	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Provide monograph and COA of Butchers Broom Extract.</li> </ul>



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> <li>Provide safety undertaking of the applied formulation on notarized stamp paper duly signed by the owner of the firm.</li> </ul>
<b>M/s Nestro Pharma International, Plot No. 29, Street No. S-2, RCCI Industrial Estate, Rawat. (E. No. 001130)</b>		
77.	NESCOLD BALM	<p>EEC decided to defer the application for enlistment on following reasons:</p> <ul style="list-style-type: none"> <li>The firm applied same formulation with brand name nestro-Wix Balm Balm with insignificant difference, need clarification.</li> <li>Form-3 needs to be revised w.r.t. mentioning the weight of balm against which strengths of active are mentioned.</li> </ul>
78.	NESDEX BALM	EEC decided to defer the application for enlistment for Provision of monograph of cajuput oil.
79.	NIODEX BALM	<p>EEC decided to defer the application for enlistment on following reasons:</p> <ul style="list-style-type: none"> <li>Provide monograph of cajuput oil.</li> <li>Form-3 needs to be revised w.r.t. mentioning the weight of balm against which strengths of active are mentioned.</li> </ul>
80.	NESBION LOTION	<p>EEC decided to defer the application for enlistment on following reasons:</p> <ul style="list-style-type: none"> <li>Justify the applied formulation as health product/supplement as defined under SRO 412(I)/2014.</li> <li>Applicant shall support applications through necessary proof or evidence, to prove quality, safety and efficacy of the product.</li> <li>Provide monograph of Chrysanthemum cinerariifolium extract.</li> <li>Justify the role of each ingredient as active ingredient.</li> </ul>
81.	SCABIRON CREAM	<p>EEC decided to defer the application for enlistment on following reasons:</p> <ul style="list-style-type: none"> <li>Justify the applied formulation as health product/supplement as defined under SRO 412(I)/2014.</li> <li>Applicant shall support applications through necessary proof or evidence, to prove quality, safety and efficacy of the product.</li> <li>Provide monograph of Chrysanthemum cinerariifolium extract.</li> <li>Justify the role of each ingredient as active ingredient.</li> </ul>
82.	NESTRO-WIX BALM	<p>EEC decided to defer the application for enlistment on following reasons:</p> <ul style="list-style-type: none"> <li>The firm applied same formulation with brand name Nescold Balm with insignificant difference, need clarification.</li> <li>Form-3 needs to be revised w.r.t. mentioning the weight of balm against which strengths of active are mentioned.</li> </ul>
83.	NESRUB GEL	<p>EEC decided to defer the application for enlistment on following reasons:</p> <ul style="list-style-type: none"> <li>Justify the applied formulation as health product/supplement as defined under SRO 412(I)/2014.</li> <li>Applicant shall support applications through necessary proof or evidence, to prove quality, safety and efficacy of the product.</li> </ul>
84.	NESMOGEL GEL	EEC decided to defer the application for enlistment to seek clarification regarding use of herbs in the formulation while possess nutraceutical facility.
85.	ALGITOR LOTION	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Justify the applied formulation as health product/supplement as defined under SRO 412(I)/2014.</li> <li>Applicant shall support applications through necessary proof or evidence, to prove quality, safety and efficacy of the product.</li> </ul>
86.	VITA-MORE FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Specify the type of protein, fat, carbohydrate being used in the formulation and revise form-3 accordingly as per monograph.</li> <li>Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
87.	KIDSGROW FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide monograph and specify the type of protein, fat, carbohydrate being used in the formulation and revise form-3 accordingly as per monograph.</li> <li>Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
88.	MOM-CARE FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide monograph and specify the type of protein, fat, DHA, carbohydrate being used in the formulation and revise form-3 accordingly as per monograph.</li> <li>Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
89.	MULTINEST FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide monograph and specify the type of protein, fat, HMB, carbohydrate being used in the formulation and revise form-3 accordingly as per monograph.</li> <li>Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
90.	VALIDUS FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide monograph and specify the type of protein, fat, DHA, carbohydrate being used in the formulation and revise form-3 accordingly as per monograph.</li> <li>Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
91.	NESTRO-VITS FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide monograph and specify the type of protein, fat, DHA, carbohydrate being used in the formulation and revise form-3 accordingly as per monograph.</li> <li>Convert strength from percentage to mg.</li> <li>Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
92.	NESTRO COMPLAN FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p>

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> </ul>
93.	FEMIGAIN FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>• Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
94.	VITAGRAND FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Provide monograph and specify the type of protein, fat, DHA, carbohydrate, fiber, polyols being used in the formulation and revise form-3 accordingly as per monograph.</li> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>• Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
95.	HI-DIET PLUS FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Justify the strengths of sodium and potassium given in “MIU”.</li> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>• Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
96.	NUTRIVIN FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Provide monograph and specify the type of protein, fat, carbohydrate, fiber being used in the formulation and revise form-3 accordingly as per monograph.</li> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>• Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
97.	POWER GAIN FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Provide monograph and specify the type of protein, fat, carbohydrate, fiber being used in the formulation and revise form-3 accordingly as per monograph.</li> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>• Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
98.	ANERGIX FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Provide monograph and specify the type of protein, fat, carbohydrate being used in the formulation and revise form-3 accordingly as per monograph.</li> </ul>





S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>• Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
99.	PROVITS FOOD SUPPLEMENT	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Provide monograph and specify the type of protein, fat, carbohydrate being used in the formulation and revise form-3 accordingly as per monograph.</li> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>• Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and milk.</li> </ul>
<p align="center"><b>M/s Tehseen Industries, Plot NO.54/55B Punjab Small Industrial Estate 8-km Kasur, 44-KM Ferozpur Road, Lahore. (E. No. 00714)</b></p>		
100.	BURNEEM CREAM	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> <li>• Properly filled Form-3 needs to be applied, signed and stamped by the owner of the firm.</li> <li>• Provide evidence regarding the safety and efficacy of applied formulation.</li> <li>• Justify the applied formulation as nutraceutical health product defined under SRO 412(I)/2014.</li> </ul>
101.	PILOSIL CREAM	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> <li>• Properly filled Form-3 needs to be applied, signed and stamped by the owner of the firm.</li> <li>• Provide evidence regarding the safety and efficacy of applied formulation.</li> <li>• Justify the applied formulation as nutraceutical health product defined under SRO 412(I)/2014.</li> </ul>
102.	HIDEITCH LOTION	EEC decided to defer the application for enlistment for the change of brand name.
103.	MITRIN LOTION	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> <li>• Properly filled Form-3 needs to be applied, signed and stamped by the owner of the firm.</li> <li>• Provide evidence regarding the safety and efficacy of applied formulation.</li> <li>• Justify the applied formulation as nutraceutical health product defined under SRO 412(I)/2014.</li> </ul>
104.	RENUÉ BIOTIN GEL	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> <li>• Properly filled Form-3 needs to be applied, signed and stamped by the owner of the firm.</li> <li>• Provide evidence regarding the safety and efficacy of applied formulation.</li> <li>• Justify the applied formulation as nutraceutical health product defined under SRO 412(I)/2014.</li> </ul>
105.	AKNO CREAM	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Properly filled Form-3 needs to be applied, signed and stamped by the owner of the firm.</li> <li>Provide evidence regarding the safety and efficacy of applied formulation.</li> <li>Justify the applied formulation as nutraceutical health product defined under SRO 412(I)/2014.</li> </ul>
106.	V-CLEAR LOTION	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Brand name needs to be changed.</li> <li>Properly filled Form-3 needs to be applied, signed and stamped by the owner of the firm.</li> <li>Provide evidence regarding the safety and efficacy of applied formulation.</li> <li>Justify the applied formulation as nutraceutical health product defined under SRO 412(I)/2014.</li> </ul>
107.	SULPHURX CREAM	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Brand name needs to be changed.</li> <li>Properly filled Form-3 needs to be applied, signed and stamped by the owner of the firm.</li> <li>Provide evidence regarding the safety and efficacy of applied formulation.</li> <li>Justify the applied formulation as nutraceutical health product defined under SRO 412(I)/2014.</li> </ul>
<b>M/s Bio-Med Pharma, Plot No.DP-28/1, Sector 12 C, North Karachi Industrial Area, Karachi-Pakistan. (E. No.00623)</b>		
108.	BIO-MED PHARMA WRINK-MED CREAM	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Brand name needs to be changed.</li> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> </ul>
109.	BIO-MED PHARMA AKNI-MED CREAM	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Convert strengths from percentage to mg per gram or ml per gram of formulation.</li> <li>Brand name needs to be changed.</li> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> </ul>
110.	BIO-MED PHARMA Arti-Med CREAM	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Brand name needs to be changed.</li> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> <li>Provide monograph of all ingredient.</li> </ul>
111.	BIO-MED Pharma PAN-MED	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Brand name needs to be changed.</li> <li>The applied formulation contains Winter green oil which is added in the list of common molecules.</li> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> </ul>
112.	BIO-MED Pharma Sero Med Cream	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> <li>Provide monograph of all ingredients.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Revise form-3 w.r.t. names and specification of each ingredient as per monographs.</li> </ul>
113.	BIO-MED Pharma FUN-MED Cream	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> <li>Provide monograph of all ingredients.</li> <li>Revise form-3 w.r.t. names and specification of each ingredient as per monographs.</li> </ul>
114.	BIO-MED PHARMA D-MED Cream	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide clinical evidence regarding topical use of Vitamin D3 as Nutritional Supplement/ Nutraceutical Health Product.</li> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> </ul>
115.	Bio Med Pharma Hemo-Med Cream	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> <li>Provide monograph of all ingredients.</li> <li>Revise form-3 w.r.t. names and specification of each ingredient as per monographs.</li> </ul>
116.	BIO MED PHARMA WITSOL PLUS Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>The applied formulation contains toxic ingredient i.e. Borago officinalis extract, submit clarification regarding safety of applied formulation.</li> <li>Provide monograph of all ingredients.</li> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> <li>Revise form-3 w.r.t. names and specification of each ingredient as per monographs</li> </ul>
117.	BIO MED PHARMA WITSOL Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> </ul>
118.	BIOMED Pharma USICURE Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> </ul>
119.	BIO MED PHARMA IRROSTONE Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> <li>Revise form-3 w.r.t. names and specification of each ingredient as per monographs.</li> <li>Provide monograph of all ingredients.</li> </ul>
120.	BIO-MED PHARMA BIO-CID SACHET	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> <li>Revise form-3 w.r.t. names and specification of each ingredient as per monographs.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Provide monograph of all ingredients.</li> </ul>
121.	BIO-MED PHARMA BIOCAL SACHET	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> <li>• Provide monograph of relevant salt of iron being used in the formulation.</li> <li>• Revised form-3 w.r.t. mentioning the salt of iron being used in the formulation.</li> </ul>
122.	Bio Med's Win Plus-F Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• The applied formulation contains Biotin 5mg which exceeds the RDA/upper tolerable limits.</li> <li>• Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> </ul>
123.	Bio Med's SILIMED Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> <li>• Provide monographs of Dandelion root and Artichoke leaf powder.</li> <li>• Revise form-3 w.r.t. names and specification of each ingredient as per monograph.</li> <li>• Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> </ul>
124.	Bio Med's Silimed Plus Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> <li>• Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> </ul>
125.	Bio Med's PC CURE Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Brand names needs to be changed.</li> <li>• Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> <li>• Revise form-3 w.r.t. names and specification of each ingredient as per monographs.</li> <li>• Specify the type of vitamin K on form-3 being used in the formulation.</li> <li>• The dose of selenium i.e. 300mcg exceeds RDA/upper tolerable limits i.e. 200mcg.</li> <li>• Mention salt of selenium and manganese being used in the formulation and provide their monographs.</li> <li>• Justify the use of citric acid as active ingredient.</li> <li>• The applied formulation contains melatonin which is added in the list of common molecules.</li> </ul>
126.	Bio Med's MH-Collagen Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> <li>• Provide monograph of all ingredients except Vitamin C and MSM.</li> <li>• Revise form-3 w.r.t. names and specification of each ingredient as per monographs.</li> </ul>
127.	Bio Med's Kid-Med Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Brand names needs to be changed.</li> <li>• Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> <li>• Provide monograph of all ingredients.</li> <li>• Revise form-3 w.r.t. names and specification of each ingredient as per monographs.</li> </ul>
128.	Bio Med's ERECTIFERT Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Brand names needs to be changed.</li> <li>• Provide undertaking regarding submission of stability data on company's letter head duly signed and stamped by the Owner of the firm.</li> <li>• Provide monograph of all ingredients.</li> <li>• Revise form-3 w.r.t. names and specification of each ingredient as per monographs.</li> <li>• Specify the type of vitamin K on form-3 being used in the formulation.</li> <li>• The dose of selenium i.e. 300mcg exceeds RDA/upper tolerable limits i.e. 200mcg.</li> <li>• Mention salt of selenium being used in the formulation.</li> </ul>
129.	Bio Med's Amino Whey Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Confirmation regarding availability of food supplement section.</li> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>• Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein.</li> <li>• Mention salt of selenium and iodine being used in the formulation.</li> <li>• Justify the dose of zinc sulphate i.e. 400mcg</li> <li>• The dose of selenium i.e. 200mg exceeds RDA/upper tolerable limits i.e. 200mcg.</li> <li>• Provide monograph of whey protein (Raw material &amp; Finished) and Iron Bisglycinate.</li> <li>• Form-3 needs to be revised w.r.t. specification of each ingredient as per monograph.</li> </ul>
130.	Bio Med's Bio-Sure Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Confirmation regarding availability of food supplement section.</li> <li>• Provide monograph and specify the type of protein, fat, carbohydrate being used in the formulation and revise form-3 accordingly as per monograph.</li> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>• Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein.</li> <li>• Form-3 needs to be revised w.r.t. specification of each ingredient as per monograph e.g. Pantothenic acid (Ph.Canda).</li> <li>• The applied formulation contains ammonium chloride which is added in the list of common molecules.</li> </ul>
<p><b>M/s. Z-JANS Pharmaceuticals (Pvt.) Ltd., 148-A, Hayatabad Industrial Estate, Peshawar. (E.No.00224)</b></p>		
131.	Bonus Drops	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> <li>• Form-3 needs to be revised w.r.t. mentioning the specification of ingredient.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Application for enlistment of product (Form-3) is not signed by the owner of the firm.</li> <li>• Provide undertaking regarding submission of stability data supporting shelf life on company's letter head duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding resemblance of brand name on notarized stamp paper duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding truthfulness/correctness of information on notarized stamp paper duly signed and stamped by the owner of the firm.</li> </ul>
132.	Zecal-M Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the salts of each ingredient as per monograph.</li> <li>• Provide monograph of all ingredients.</li> <li>• Provide undertaking regarding submission of stability data supporting shelf life on company's letter head duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding resemblance of brand name on notarized stamp paper duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding truthfulness/correctness of information on notarized stamp paper duly signed and stamped by the owner of the firm.</li> </ul>
133.	Bone-C Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Application for enlistment of product (Form-3) is not signed by the owner of the firm.</li> <li>• Provide undertaking regarding submission of stability data supporting shelf life on company's letter head duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding resemblance of brand name on notarized stamp paper duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding truthfulness/correctness of information on notarized stamp paper duly signed and stamped by the owner of the firm.</li> </ul>
134.	Iro-F Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Provide monograph of Iron (as Iron Polymaltose).</li> <li>• Provide undertaking regarding submission of stability data supporting shelf life on company's letter head duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding resemblance of brand name on notarized stamp paper duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding truthfulness/correctness of information on notarized stamp paper duly signed and stamped by the owner of the firm.</li> </ul>
135.	Zecod Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Provide undertaking regarding submission of stability data supporting shelf life on company's letter head duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding resemblance of brand name on notarized stamp paper duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding truthfulness/correctness of information on notarized stamp paper duly signed and stamped by the owner of the firm.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
136.	Helix Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Provide monograph of Hedera helix in its extract form.</li> <li>• Provide undertaking regarding submission of stability data supporting shelf life on company's letter head duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding resemblance of brand name on notarized stamp paper duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding truthfulness/correctness of information on notarized stamp paper duly signed and stamped by the owner of the firm.</li> </ul>
137.	Syrup Zeron Plus	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the salts of each ingredient as per monograph.</li> <li>• Provide monograph of all ingredients.</li> <li>• Provide undertaking regarding submission of stability data supporting shelf life on company's letter head duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding resemblance of brand name on notarized stamp paper duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding truthfulness/correctness of information on notarized stamp paper duly signed and stamped by the owner of the firm.</li> </ul>
138.	Soda Cal Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• The applied formulation contains sodium alginate which is registered as drug.</li> <li>• The applied formulation contains Sodium Hydrogen Carbonate which is added in the list of common molecules.</li> <li>• Provide undertaking regarding submission of stability data supporting shelf life on company's letter head duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding resemblance of brand name on notarized stamp paper duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding truthfulness/correctness of information on notarized stamp paper duly signed and stamped by the owner of the firm.</li> </ul>
139.	Cal-Vit Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>• Provide monograph of Calcium lactate gluconate.</li> <li>• Provide undertaking regarding submission of stability data supporting shelf life on company's letter head duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding resemblance of brand name on notarized stamp paper duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding truthfulness/correctness of information on notarized stamp paper duly signed and stamped by the owner of the firm.</li> </ul>
140.	Vegor Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Provide undertaking regarding submission of stability data supporting shelf life on company's letter head duly signed and stamped by the owner of the firm.</li> </ul>

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Provide undertaking regarding resemblance of brand name on notarized stamp paper duly signed and stamped by the owner of the firm.</li> <li>• Provide undertaking regarding truthfulness/correctness of information on notarized stamp paper duly signed and stamped by the owner of the firm.</li> </ul>
<b>M/s Ismail Industries Limited, G 22-23, Hub Industrial Estate, H.I.T.E. Hud, District, Lasbela Baluchistan. (E. No. 00942)</b>		
141.	XGEN RUTF	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the exact strength of each ingredient keeping in view the Recommended Daily Allowance (RDA) / Upper tolerable limits.</li> <li>• Form-3 needs to be revised w.r.t. mentioning the Specification (USP, BP, etc.) of each ingredient.</li> <li>• Justify that the single ingredient like DCP can deliver each elemental ingredient in exact strength as mentioned on form-3.</li> <li>• Provide official monograph of each ingredient.</li> <li>• Notarized undertaking regarding brand name resemblance is missing</li> <li>• Notarized undertaking regarding correctness/truthfulness of information is missing.</li> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>• Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and skimmed milk.</li> </ul>
142.	XGen LNS-PLW	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the exact strength of each ingredient keeping in view the Recommended Daily Allowance (RDA) / Upper tolerable limits.</li> <li>• Form-3 needs to be revised w.r.t. mentioning the Specification (USP, BP, etc.) of each ingredient.</li> <li>• Justify that the single ingredient like DCP can deliver each elemental ingredient in exact strength as mentioned on form-3.</li> <li>• Provide official monograph of each ingredient.</li> <li>• Notarized undertaking regarding brand name resemblance is missing</li> <li>• Notarized undertaking regarding correctness/truthfulness of information is missing.</li> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>• Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and skimmed milk.</li> </ul>
143.	XGen RUSF	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the exact strength of each ingredient keeping in view the Recommended Daily Allowance (RDA) / Upper tolerable limits.</li> <li>• Form-3 needs to be revised w.r.t. mentioning the Specification (USP, BP, etc.) of each ingredient.</li> <li>• Justify that the single ingredient like DCP can deliver each elemental ingredient in exact strength as mentioned on form-3.</li> <li>• Provide official monograph of each ingredient.</li> <li>• Notarized undertaking regarding brand name resemblance is missing</li> </ul>





S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Notarized undertaking regarding correctness/truthfulness of information is missing.</li> <li>• Provide testing method including assay for finished product mentioning the release specifications of each ingredient as per monograph.</li> <li>• Provide evidence for availability of specific testing facility (HPLC column, apparatus, equipment etc.) for protein/Amino Acid and skimmed milk.</li> </ul>
<b>M/s Haven Pharmaceuticals Pvt. Ltd., Plot No. 65-A, M-3, Industrial Estate, Sahianwala, Faisalabad (E. No. 00985)</b>		
144.	Act Fast Gel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>• Provide monograph of all ingredients.</li> <li>• Specify the type of capsicum (oleoresin etc.) being used in the formulation as per monograph.</li> </ul>
145.	Actum Gel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>• Provide monograph of all ingredients.</li> <li>• The applied formulation contains wintergreen oil which is added in the list of common molecules.</li> <li>• Specify the type of capsicum (oleoresin etc.) being used in the formulation as per monograph.</li> <li>• The applied formulation in duplication with Reliever Gel.</li> </ul>
146.	Finch-Pain Gel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>• Provide monograph of all ingredients.</li> <li>• The applied formulation contains wintergreen oil which is added in the list of common molecules.</li> <li>• Specify the type of capsicum (oleoresin etc.) being used in the formulation as per monograph.</li> <li>• The applied formulation in duplication with Relaxor Gel.</li> </ul>
147.	Joint-Fit Gel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>• Provide monograph of all ingredients.</li> <li>• The applied formulation contains Glucosamine which is added in the list of common molecules.</li> </ul>
148.	Minter Gel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>• Provide monograph of all ingredients.</li> <li>• The applied formulation contains wintergreen oil which is added in the list of common molecules.</li> <li>• Specify the type of capsicum (oleoresin etc.) being used in the formulation as per monograph.</li> </ul>
149.	Minter Lotion	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>• Provide monograph of all ingredients.</li> <li>• The applied formulation contains wintergreen oil which is added in the list of common molecules.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Specify the type of capsicum (oleoresin etc.) being used in the formulation as per monograph.</li> </ul>
150.	Orthocare Gel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>Provide monograph of all ingredients.</li> <li>Specify the type of capsicum (oleoresin etc.) being used in the formulation as per monograph.</li> </ul>
151.	Ortho-Nil Gel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>Provide monograph of all ingredients.</li> <li>Specify the type of capcisin (oleoresin etc.) being used in the formulation as per monograph.</li> </ul>
152.	Pain-Stat Gel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>Provide monograph of all ingredients.</li> <li>Specify the type of capsicum (oleoresin etc.) being used in the formulation as per monograph.</li> </ul>
153.	Pain-Nil Gel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>Provide monograph of all ingredients.</li> <li>Specify the type of capsicum (oleoresin etc.) being used in the formulation as per monograph.</li> </ul>
154.	Relaxor Gel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>The applied formulation contains wintergreen oil which is added in the list of common molecules.</li> <li>Specify the type of capsicum (oleoresin etc.) being used in the formulation as per monograph.</li> <li>The applied formulation in duplication with Finch-Pain Gel.</li> </ul>
155.	Reliever Gel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>Provide monograph of all ingredients.</li> <li>The applied formulation contains wintergreen oil which is added in the list of common molecules.</li> <li>Specify the type of capsicum (oleoresin etc.) being used in the formulation as per monograph.</li> <li>The applied formulation in duplication with Actum Gel.</li> </ul>
156.	Xtra Fast Gel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient.</li> <li>Provide monograph of all ingredients.</li> </ul>
<b>M/s. Nutrifactor Laboratories (Pvt) Ltd., Plot No 4-B, Value Addition City, Khurrianwala, Faisalabad (E. No. 00324)</b>		
157.	TARZAN GUMMIES	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed.</li> <li>Justify that a single ingredient i.e. tribasic calcium phosphate (with molar weight of 502.31g/mol) can deliver 250mg Calcium and 115mg Phosphorus at the same time.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<b>Scenario:</b> To deliver 250mg calcium 734mg (34%) or 625 (40%) of tribasic calcium phosphate is required. However, 466.3mg of tribasic calcium phosphate is required to deliver 115mg of phosphorus.
158.	APPLE CIDER VINEGAR GUMMIES	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Justify the use of "Organic Pomegranate" as nutraceutical ingredient. Also specify the exact form (extract, oil, powder, crude etc.) in which it is being used in the formulation and revise form-3 accordingly.</li> </ul>
<b>M/s Mehran International, 498-D Hume Road, Quaideen Colony, Karachi agent of M/s Henan Baihuikang Biotechnology Co., Ltd., East Side of Weilai Road, Industry Cluster District Changge City, Henan Province, China (E. No. 01082)</b>		
159.	Melatonin Softgel Capsule 2.05MG	Deferred for Melatonin is added in common molecules list.
160.	Glucosamine + Chondroitin Tablets (Ezi Move Tablets)	Deferred for Glucosamine, chondroitin and hyaluronic acid are added in common molecules list.
<b>M/s Adcok Pharmaceutical (Pvt) Ltd, Lahore</b>		
161.	Norton Food Supplement	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Properly filled signed and stamped form 3 is required</li> <li>Stability studies undertaking is required</li> <li>Undertaking notarized regarding content and brand name is required</li> <li>Proof of food supplement section</li> </ul>
<b>M/s Ain Nutro, Lahore</b>		
162.	Zim-U Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
163.	Multi Pack Forte Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Undertaking regarding brand name is required</li> </ul>
164.	Ain Cobal Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Evidence of fee submission is required</li> <li>Undertaking regarding stability studies is required</li> </ul>
<b>M/s Alaq Laboratories, Lahore</b>		
165.	Socal-D Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
166.	Mark-D Drop	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and



S.No (1)	Brand name (2)	Decision (3)
		processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
167.	Neurox Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
168.	Recover Plus Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
169.	Re'Cal-D Suspension	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
170.	Abex Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
171.	Iron Plus Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Alomed Curatives, Islamabad</b>		
172.	Grow Mix 50 Oral Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Undertaking regarding brand name is required</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
173.	Ak Premix L Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Undertaking notarized regarding content and brand name is required</li> </ul>
174.	Ak Electrovit Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Undertaking notarized regarding content and brand name is required</li> </ul>
175.	Ak Immune Booster Oral Solution	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Undertaking notarized regarding content and brand name is required</li> </ul>
176.	Ak Supervit Oral Solution	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Method of testing of amino acid as in finished formulation is required</li> <li>• Specification of active ingredients in formulation is required</li> </ul>
177.	Ak Sel E Oral Solution	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Undertaking notarized regarding content and brand name is required</li> </ul>
178.	Adek Forte Solution	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Undertaking regarding brand name is required</li> </ul>
179.	Mintovit 1000MI Solution	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Undertaking notarized regarding content and brand name is required</li> </ul>
180.	Ak Bromint Solution	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
181.	Ak Levovit Solution	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Angel Human Health Nutraceutical, Faisalabad</b>		
182.	Enliven Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division



S.No (1)	Brand name (2)	Decision (3)
		of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
183.	P-Win Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
184.	Aim Tizer Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
185.	Aim Cid Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
186.	Dune-C Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Apple Laboratories, Islamabad</b>		
187.	Profol M Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
188.	T-Clear Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division



S.No (1)	Brand name (2)	Decision (3)
		of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
189.	Wish 2 Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Stability studies undertaking is required</li> <li>• Evidence of fee submission along with breakage is required</li> </ul>
190.	Camzid Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Stability studies undertaking is required</li> <li>• Evidence of fee submission along with breakage is required</li> </ul>
<b>M/s Arshzik Pharma, Rawalpindi</b>		
191.	Vitamix Super Liquid	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Undertaking regarding brand name is required</li> </ul>
192.	Mintowan H S Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
193.	G.Nill Liquid	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Monograph of apsam salt and glacial acetic acid are required</li> <li>• Justification/use of product as health</li> </ul>
194.	Stress E Lyte Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
195.	Minhol Super	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Undertaking regarding stability studies is required</li> </ul>
196.	Dyno Cut	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Firm uses herbs in crude form</li> <li>• Proof/clarification of herbal liquid section</li> </ul>
<b>M/s Atzan Natural Products, Multan</b>		
197.	Milkan Mineral Forte Granules Granules	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since



S.No (1)	Brand name (2)	Decision (3)
		computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
198.	Dairy Queen Mineral Forte Granules Granules	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
199.	Vet. Mineral Forte Granules Granules	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
200.	Digestofos Plus Powder Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Avant Pharmaceutical, Karachi</b>		
201.	Power Plus Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• The firm uses herbs in crude form</li> <li>• Confirmation of herbal tablet section</li> </ul>
<b>M/s Awacs Laboratories, Rawalpindi</b>		
202.	Hemocyl Cream	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Monographs of hamamelis,Stellaria and Lippia nodiflora extract are required</li> <li>• Brand name needs to be changed</li> <li>• The applied formulation contains toxic plant berberis aristate</li> </ul>
203.	Cartinox Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.





S.No (1)	Brand name (2)	Decision (3)
204.	Pro-Vig Cream	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Firm uses herbs in crude form</li> <li>• Confirmation/proof of cream herbal section</li> </ul>
205.	Vg-Wash Liquid	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• The applied formulation contains ingredient which is in list of common molecule</li> <li>• Justification and use of formulation as health product</li> </ul>
206.	Reactivan Liquid	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Monograph of (fulvic acid)Salajet and withania somnifera extract is required</li> </ul>
207.	Synaps-Vgh Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Monograph and use justification of Huperzine is required</li> <li>• Brand name needs to be changed</li> <li>• Monograph of vinpocetine,bacopa monnieri extract are required</li> </ul>
208.	Fibo-Z Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
209.	Probrain Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Monographs of extract of Lavandula,Bacopa monnieri and red ginseng extract are required</li> </ul>
210.	Vita Jewels Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
211.	Zix-Ad Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Firm uses herbs in crude form</li> <li>• Confirmation/proof of herbal syrup section</li> </ul>
212.	Cartinox Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Justification of use of two formulation in single pack</li> </ul>
213.	Glyciron Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant



S.No (1)	Brand name (2)	Decision (3)
		product application to check its status whether it has been disposed of or otherwise.
214.	Reactivan Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Monograph of Withania somnifera extract is required</li> <li>• Monograph of salaget(fulvic acid) is required</li> </ul>
215.	Turocare Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Monograph of taurine is required</li> <li>• Properly filled signed and stamped form 3 is required</li> </ul>
216.	Tri-On Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
217.	Ivyol Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> </ul>
218.	Kalnate-D Drop	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Undertaking regarding brand name is required</li> </ul>
219.	Msm Cream	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Monograph of sesame oil is required</li> </ul>
220.	V2M Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Monograph of EPA,DHAand Omega 3 are required</li> </ul>
221.	Cranmose Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Specify the strength per unit delivery of sachet or per pack</li> </ul>
222.	Huskal-C Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form3 is required</li> <li>• Undertaking regarding stability studies is required</li> <li>• Brand name needs to be changed</li> <li>• Undertaking notarized regarding brand name and content of dossier are required</li> </ul>
223.	Wittles Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Monograph of Foeniculum vulgare extract is required</li> </ul>
<b>M/s Bio Life Enterprises Nutraceuticals, Rawalpindi</b>		
224.	Oseoprime Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division



S.No (1)	Brand name (2)	Decision (3)
		of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
225.	Fit Fert Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> <li>• Evidence of fee submission along with breakage is required</li> <li>• Monograph of Tribulus terrestris,withania somniferum,royal jelly and wheat germ oil are required</li> </ul>
226.	Pcos-Fix Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> <li>• Evidence of fee submission along with breakage is required</li> </ul>
227.	Mobility Spray	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Undertaking regarding content of dossier is required</li> </ul>
228.	Ferromate Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> <li>• Evidence of fee submission along with breakage is required</li> <li>• Monograph of chelated Iron is required</li> </ul>
229.	Lipron Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
230.	Multi Plus Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> <li>• Evidence of fee submission along with breakage is required</li> </ul>
231.	Osforte Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Undertaking regarding content of dossier is required</li> </ul>
232.	Nutra Plex Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
233.	Pica-A Syrup	EEC decided to defer the application for enlistment due to following reasons:



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Evidence of fee submission along with breakage of fee is required</li> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> </ul>
234.	Kolfar-D Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> <li>Monograph of omega 3 is required</li> </ul>
235.	Edo-Vit Tablet	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
236.	XI-Vit Tablet	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
237.	Osforte Tablet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Undertaking regarding content of dossier is required</li> </ul>
238.	Multivair Tablet	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
239.	Cvd-3 Tablet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Evidence of fee submission along with breakage of fee is required</li> <li>Monograph of chelated iron is required</li> </ul>
240.	Lipron Tablet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Evidence of fee submission along with breakage of fee is required</li> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> <li>Monograph of chelated iron is required</li> </ul>
241.	Kolfar-D Tablet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Evidence of fee submission along with breakage of fee is required</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> </ul>
242.	Folician Plus Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Evidence of fee submission along with breakage of fee is required</li> </ul>
243.	Xobex-Z Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Evidence of fee submission along with breakage of fee is required</li> <li>Monograph of chelated iron is required</li> </ul>
244.	Axis Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Monograph of Tribulus terrestris extyract and bacopia monneri extract is required</li> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> </ul>
245.	Krack Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
246.	Cran-P Sachet	EEC decided to defer the application for enlistment due to following reasons: Proof/clarification of probiotic sachet section
247.	Fovit Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Evidence of fee submission along with breakage of fee is required</li> </ul>
248.	Kuff-X Syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
249.	Neomin Syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
250.	Due+ Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> <li>Stability studies undertaking is required</li> </ul>
251.	Procium Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> <li>Stability studies undertaking is required</li> </ul>
252.	Conslac Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in

*(Signature)*

S.No (1)	Brand name (2)	Decision (3)
		the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
253.	Ferron Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
254.	Aronechel Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
255.	Kobi Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Firm uses herbs in crude form</li> <li>• Evidence of fee submission along with breakage of fee is required</li> <li>• Proof/clarification of herbal syrup section</li> </ul>
256.	Cobrain Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Evidence of fee submission along with breakage of fee is required</li> </ul>
257.	Ginxol Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> <li>• Monograph of omega 3 is required</li> </ul>
258.	Vari-D Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
259.	Ferron Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Monograph of chelated iron is required</li> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> </ul>
260.	G-Cal-D Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product



S.No (1)	Brand name (2)	Decision (3)
		applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
261.	Ginxol Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> <li>Monograph of omega 3 is required</li> </ul>
262.	Gs Vit + Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
263.	Nervefit Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Undertaking regarding content of dossier is required</li> </ul>
264.	Procium Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in the formulation</li> <li>Stability studies undertaking is required</li> </ul>
265.	Reglow Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Monograph of proanthocyanidines,pycnogel</li> </ul>
266.	Dermage Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Undertaking regarding content of dossier is required</li> </ul>
<b>M/s Bio Natural Solution, Islamabad</b>		
267.	Fam Live Plus Liquid	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Properly filled,signed stamped form 3 is required</li> <li>Undertaking notarized regarding content and brand name is required</li> <li>Stability studies undertaking is required</li> <li>The applied formulation contains silymarin which is in list of common molecule and deferred till the finalization of policy decision regarding common molecule</li> </ul>
268.	Electro Cf Liquid	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Properly filled,signed stamped form 3 is required</li> <li>Undertaking notarized regarding content and brand name is required</li> <li>Stability studies undertaking is required</li> <li>Firm uses herbs in crude form</li> <li>The applied formulation contains sodium bicarbonate which is in list of common molecule deferred till the finalization of policy decision regarding common molecule</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
269.	Minto Mix Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
270.	Fam Immune Oral Solution	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Properly filled,signed stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Stability studies undertaking is required</li> </ul>
271.	Fibro Mass Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Properly filled,signed stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Stability studies undertaking is required</li> <li>• Firm uses herbs in crude form</li> <li>• The applied formulation contains sodium bicarbonate which is in list of common molecule and deferred till the finalization of policy decision regarding common molecule</li> </ul>
272.	Vit-C Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
273.	Urimide Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Properly filled,signed stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Stability studies undertaking is required</li> <li>• Firm uses herbs in crude form</li> <li>• Confirmation of herbal powder section</li> </ul>
274.	Penta Max Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Properly filled,signed stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Stability studies undertaking is required</li> </ul>
<b>M/s Biocure Pharmaceutical, Lahore</b>		
275.	Pinocid Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product





S.No (1)	Brand name (2)	Decision (3)
		applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
276.	Fumisid Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
277.	Destan Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
278.	C-San Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
279.	Stress Stop	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Bion Life Sciences, Lahore</b>		
280.	Ovuline Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
281.	Cofnext Sugar Free Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Firm uses herbs in crude form</li> <li>• Confirmation/proof of herbal syrup section</li> </ul>
<b>M/s Calgan Phyto Pharma Pvt Ltd, Lahore</b>		



S.No (1)	Brand name (2)	Decision (3)
282.	Laxagel Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Classic Nutraceutical Labs, Peshawar</b>		
283.	Daily Milk Plus Granules	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
284.	Lacta Plus Granules	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form3 is required</li> <li>• Undertaking(notarized) regarding brand name and content of dossier are required</li> <li>• Brand name needs to be changed</li> </ul>
285.	Taqatwar Granules	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form3 is required</li> <li>• Undertaking(notarized) regarding brand name and content of dossier are required</li> <li>• Brand name needs to be changed</li> </ul>
286.	Hepatonol Liquid	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form3 is required</li> <li>• Undertaking(notarized) regarding brand name and content of dossier are required</li> <li>• Brand name needs to be changed</li> </ul>
287.	Stomach Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form3 is required</li> <li>• Undertaking(notarized) regarding brand name and content of dossier are required</li> <li>• Brand name needs to be changed</li> <li>• The applied formulation contains toxic plant Nux vomica</li> <li>• The applied formulation contains ingredient which is in list of common molecule and deferred till the finalization of policy decision regarding common molecule</li> </ul>
288.	Saline Electuary Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form3 is required</li> <li>• Undertaking(notarized) regarding brand name and content of dossier are required</li> <li>• Brand name needs to be changed</li> </ul>
289.	Dairy Milk Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form3 is required</li> <li>• Undertaking(notarized) regarding brand name and content of dossier are required</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Brand name needs to be changed</li> </ul>
290.	Dairy Bone Phosphate Powder	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Properly filled signed and stamped form3 is required</li> <li>Undertaking(notarized) regarding brand name and content of dossier are required</li> <li>Brand name needs to be changed</li> </ul>
291.	Copsulf Powder	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Properly filled signed and stamped form3 is required</li> <li>Undertaking(notarized) regarding brand name and content of dossier are required</li> <li>Brand name needs to be changed</li> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation</li> </ul>
292.	Colic Green Syrup	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
293.	Vit E Fort	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Properly filled signed and stamped form3 is required</li> <li>Undertaking(notarized) regarding brand name and content of dossier are required</li> <li>Brand name needs to be changed</li> </ul>
294.	Nutacid Rr	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Properly filled signed and stamped form3 is required</li> <li>Undertaking(notarized) regarding brand name and content of dossier are required</li> </ul>
295.	Bromo Forte	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Properly filled signed and stamped form3 is required</li> <li>Undertaking(notarized) regarding brand name and content of dossier are required</li> <li>Brand name needs to be changed</li> </ul>
296.	Bio Flush	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Properly filled signed and stamped form3 is required</li> <li>Undertaking(notarized) regarding brand name and content of dossier are required</li> <li>Brand name needs to be changed</li> </ul>
<b>M/s Cosmo Pharma International Pvt Ltd, Karachi</b>		
297.	Piles-Ye Cream	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Monograph of Sulphur rich oil shale extract,arachishypogea extract,syzygium aromatic extract,mentha arvensis extract are required</li> <li>Properly filled signed and stamped form 3 is required</li> </ul>
298.	Piles-Ex Sachet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Monograph of berberry extract is required</li> </ul>
299.	Super Warts Remover	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Crystolite Pharmaceuticals, Islamabad</b>		
300.	Visolite Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Form 3 properly signed and stamped is required</li> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation</li> </ul>
301.	Folister Plus Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Form 3 properly signed and stamped is required</li> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation</li> </ul>
302.	Folister Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Eon Pharmacy, Karachi</b>		
303.	Ostial Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
304.	Gco-3 Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Festel Neutraceuticals, Lahore</b>		
305.	Festcid Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent



S.No (1)	Brand name (2)	Decision (3)
		preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
306.	Irion-F Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Evidence of fee submission is required</li> </ul>
307.	Progin Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Evidence of fee submission is required</li> <li>• Firm uses herbs in crude form</li> <li>• Confirmation herbal syrup section</li> </ul>
308.	Bio-Ton Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Evidence of fee submission is required</li> </ul>
309.	Biosgon Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
310.	Ostelin Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Evidence of fee submission is required</li> </ul>
<b>M/s Genbiotech Nutraceuticals, Islamabad</b>		
311.	Mcfol Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
312.	Fertifix Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in



S.No (1)	Brand name (2)	Decision (3)
		the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Gluck Laboratories Pvt Ltd, Lahore</b>		
313.	Glufur Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Signed and stamped form 3 is required</li> <li>Stability studies undertaking is required</li> </ul>
314.	Appup Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Firm uses herbs in crude form</li> <li>Proof/clarification regarding herbal syrup section</li> </ul>
315.	Apifed Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Firm uses herbs in crude form</li> <li>Proof/clarification regarding herbal syrup section</li> </ul>
<b>M/s Greektec Nutraceutical, Karachi</b>		
316.	Myofem Sachet	<ul style="list-style-type: none"> <li>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</li> </ul>
<b>M/s GreenMan Pharmaceuticals, Rawalpindi</b>		
317.	Masha Hi-Diet Supplement	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
318.	Right Detox Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
319.	Ultrawits Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant



S.No (1)	Brand name (2)	Decision (3)
		product application to check its status whether it has been disposed of or otherwise.
<b>M/s Hale Pharma, Lahore</b>		
320.	Core-8 syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• The applied formulation is ossin mineral complex which is in list of common molecule and deferred till the finalization of policy decision regarding common molecule</li> </ul>
<b>M/s Himont Laboratories, Lahore</b>		
321.	Dr. Koff Lozenges	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Proof/clarification required regarding lozenges section</li> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Stability studies undertaking is required</li> </ul>
322.	Caripeptic Chewabale Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Firm uses herbs in crude form</li> <li>• Confirmation of tablet herbal section</li> <li>• Brand name needs to be changed</li> <li>• Proof/clarification required regarding lozenges section</li> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Stability studies undertaking is required</li> </ul>
<b>M/s Innova Life Sciences, Lahore</b>		
323.	Sunid Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Firm uses herbs in crude form</li> <li>• Confirmation/proof of herbal syrup section</li> </ul>
324.	Vigosun Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
325.	Nugel Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Legacy Pharmaceuticals, Peshawar</b>		
326.	Moska Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product



S.No (1)	Brand name (2)	Decision (3)
		applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Medicom Superior, Lahore</b>		
327.	Medrene Tablet	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains ingredient glucosamine,chondroitin and hyaluronic acid which is in list of common molecule deferred till the finalization of policy decision regarding common molecule
328.	Zesrin Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Stability studies undertaking is required</li> </ul> The applied formulation contains ingredient glucosamine,chondrition sulphate hyaluronic acid which is in list of common molecule and deferred till the finalization of policy decision regarding common molecule
329.	Prob Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Proof of probiotic sachet section</li> <li>• Monographs of active ingredient are required</li> </ul>
330.	We-Sure sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Proof/clarification of supplement section</li> </ul>
331.	Mizex Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Stability studies undertaking is required</li> <li>• Monograph of Tribulus extract</li> </ul>
<b>M/s Mediformers Neutrachemical, Lahore</b>		
332.	Sapcal Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
333.	Sharbat-E-Faulad Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
334.	Sharbat-E-Faulad Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division





S.No (1)	Brand name (2)	Decision (3)
		of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Medinoon Research Laboratories, Lahore</b>		
335.	Rocid Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation</li> <li>• Stability studies undertaking is required</li> </ul>
<b>M/s Miksons Healthcare SMC (Pvt) Ltd, Islamabad</b>		
336.	Bonecure Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> </ul>
337.	Osteo Grip Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
338.	Sanmax Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Specify the strength of ingredient per unit delivery/per gram of sachet</li> </ul>
339.	Neutroon Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
340.	Dawn-D Drop	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
341.	Zevic Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Monograph of pycogenol extract and arginine aspartate is required</li> </ul>
342.	Hema Plex Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division



S.No (1)	Brand name (2)	Decision (3)
		of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
343.	Reptaze Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
344.	Osteogrip Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
345.	Iron-P Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
346.	Dawn-D Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> </ul> Undertaking regarding content of dossier is required
347.	Mikcal Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of fee submission is required</li> <li>• Monograph of calcium citrate maleate is required</li> </ul>
348.	Multivit Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Specify the strength of ingredient per unit delivery/per gram of sachet</li> </ul>
349.	Garcivia Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
350.	Ova Life Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> </ul>

**M/s Mod Herbs, Karachi**



S.No (1)	Brand name (2)	Decision (3)
351.	Active Cold Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Monograph of extracts of salix alba, valeriana officinal extract are required</li> </ul>
352.	Inspire Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
353.	Basopan Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Firm uses herbs in crude form</li> <li>• Proof/clarification of herbal tablet section</li> </ul>
354.	Kufkold Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Firm uses herbs in crude form</li> <li>• Proof/clarification of herbal tablet section</li> </ul>
355.	Ca-D3 Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s MSG Nutraceuticals, Islamabad</b>		
356.	Oseomax Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation is required</li> </ul>
357.	U-Cid Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Form 3 needs to be revised w.r.t showing specification and strength of active ingredients in formulation</li> </ul>
358.	Alexa Plus Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Stability studies undertaking is required</li> </ul>
359.	Rose Met Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant



S.No (1)	Brand name (2)	Decision (3)
		product application to check its status whether it has been disposed of or otherwise.
360.	Adcorin Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
361.	Bulus Plus Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Novamed Healthcare, Lahore</b>		
362.	Once A Day Calstrong Effervescent (Lemon) Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Form 3 needs to be revised w.r.t showing specification and active ingredient calcium and magnesium in their respective salt form is required</li> </ul>
363.	Once A Day Calstrong Effervescent (Orange) Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Nutrabiotics Nutritional Life Sciences, Peshawar</b>		
364.	Leucofit Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
365.	Hsn Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation</li> <li>• Stability studies undertaking is required</li> <li>• Evidence of fee submission is required</li> <li>• Monograph of natural mixed carotenoids is required</li> </ul>
366.	Colifix Plus Drop	EEC decided to defer the application for enlistment due to following reasons:



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation</li> <li>Evidence of fee submission is required</li> <li>Brand name needs to be changed</li> <li>Firm uses herbs in crude form</li> <li>Confirmation of herbal liquid oral section</li> </ul>
367.	A-Ziar Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation</li> <li>Stability studies undertaking is required</li> <li>Evidence of fee submission is required</li> </ul>
368.	Conceive-Fm Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation</li> <li>Evidence of fee submission is required</li> <li>Brand name needs to be changed</li> </ul>
369.	Citracit-K Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>The applied formulation contains potassium citrate which is common molecule and deferred till the finalization of policy decision regarding common molecule</li> </ul>
370.	Ovasif Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation</li> <li>Evidence of fee submission is required</li> <li>Brand name needs to be changed</li> </ul>
371.	Jointfit Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>The applied formulation contains glucosamine, chondroitin sulphate and hyaluronic acid which is in list of common molecule and deferred till the finalization of policy decision regarding common molecule</li> <li>Monograph of diacerein extract is required</li> <li>Brand name needs to be changed</li> </ul>
372.	Calbon-D Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
373.	Liquid Ors Liquid	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>The applied formulation contains ORS formulation which is in list of common molecule and deferred till the finalization of policy decision regarding common molecule</li> </ul>
374.	Sebex Capsule	EEC decided to defer the application for enlistment due to following reasons:
<b>M/s Nutrasource International, Karachi</b>		
375.	Hepamits Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Fee paid for herbal products Differential fee is required</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
376.	Diracure Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Fee paid for herbal products Differential fee is required</li> <li>• Firm uses herbs in crude form</li> <li>• Confirmation of herbal syrup section</li> </ul>
377.	Asocid Suspension	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Fee paid for herbal products Differential fee is required</li> </ul>
378.	Womcare H Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Fee paid for herbal products Differential fee is required</li> <li>• Firm uses herbs in crude form</li> <li>• Confirmation of herbal syrup section</li> </ul>
379.	Pediasol Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Fee paid for herbal products Differential fee is required</li> <li>• The applied products contains formulation of ORS which is in list of common molecule and deferred till the finalization of policy decision regarding common molecule</li> </ul>
380.	N-Colic Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Fee paid for herbal products Differential fee is required</li> </ul>
381.	Skycid Suspension	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
382.	Byekuff Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Fee paid for herbal products Differential fee is required</li> </ul>
383.	Irosorce H Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
384.	Lexinor Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Fee paid for herbal products Differential fee is required</li> </ul>
385.	A-Cid Suspension	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Fee paid for herbal products Differential fee is required</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
386.	N-Colic Drop	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s PDH Health Care, Lahore</b>		
387.	Active Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
388.	Sun Veil Cream Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Phytocon International Private Limited, Lahore</b>		
389.	Bactocell Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Risen Nutraceuticals (Pvt) Ltd Lahore</b>		
390.	Risen Ors Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• The applied products contains ORS formulation which is in list of common molecule and deferred till the finalization of policy decision regarding common molecule</li> </ul>
391.	Defend Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• The applied formulation contains ossin mineral complex which is in list of common molecule and deferred till the finalization of policy decision regarding common molecule</li> <li>• Brand name needs to be changed</li> </ul>
<b>M/s Royal Laboratoies Lahore</b>		
392.	Kaif Capsules	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>The applied formulation contains ingredient which is in list of common molecule and deferred till the finalization of policy decision regarding common molecule</li> </ul>
393.	Bennimom Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Properly filled signed and stamped form 3 is required</li> <li>Monograph of moringa extract is required</li> </ul>
394.	Soasis Sachets	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Properly filled signed and stamped form 3 is required</li> </ul>
<b>M/s Siddiqui Pharma (Pvt) Ltd, Multan</b>		
395.	Lysoimmune Gold	<ul style="list-style-type: none"> <li>Application for import purpose hence discussed with other import case agenda</li> </ul>
396.	Toxin Zero	<ul style="list-style-type: none"> <li>Application for import purpose hence discussed with other import case agenda</li> </ul>
<b>M/s Sois Life Sciences, Karachi</b>		
397.	Mflor Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Properly filled signed and stamped Form-3 is required</li> </ul>
<b>M/s Tarrot Health Care, Lahore</b>		
398.	Bonac D3 50000Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Properly filled signed and stamped form 3 is required</li> <li>Brand name needs to be changed</li> </ul>
399.	Bonac D3100000Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Properly filled signed and stamped form 3 is required</li> <li>Brand name needs to be changed</li> </ul>
<b>M/s The Best Laboratories Lahore</b>		
400.	Luxor Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
401.	Api-One Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
402.	Ezi-Gut Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant





S.No (1)	Brand name (2)	Decision (3)
		product application to check its status whether it has been disposed of or otherwise.
403.	Trexa Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
404.	Gastrogel Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Trends Pharmaceuticals Lahore</b>		
405.	Vifit-D Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Viegen Pharma, Lahore</b>		
406.	Max Gold Male Tablet	Deferred for following reason: <ul style="list-style-type: none"> <li>• The monograph of tongkat ali extract,horny goat weed extract,macca root extract are required</li> <li>• Brand name needs to be changed</li> </ul>
407.	Hapirex Syrup	Deferred for following reason: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• firm uses herbs in crude form</li> <li>• clarification/proof of herbal syrup section</li> </ul>
<b>M/s Vital Phyto Pharma (Pvt) Ltd, Rawalpindi</b>		
408.	Addzee Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Evidence of fee submission is required</li> <li>• Brand name needs to be changed</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regarding stability studies is required</li> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation</li> </ul>
409.	Ferrysol Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Evidence of fee submission is required</li> <li>• Brand name needs to be changed</li> <li>• Undertaking notarized regarding content and brand name is required</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Undertaking regarding stability studies is required</li> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation</li> </ul>
410.	Gulta-C Tablet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Evidence of fee submission is required</li> <li>• Brand name needs to be changed</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regarding stability studies is required</li> <li>• Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation</li> </ul>
<b>M/s Zonex Pharma (Pvt) Ltd, Lahore</b>		
411.	Cocuf Syrup	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
412.	Rmz Toot Siyah Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Stability studies undertaking is required</li> </ul>
413.	Rmz Peppermint Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Stability studies undertaking is required</li> </ul>
414.	Zanacid Gel Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Revised form 3 is required w.r.t signature and stamped</li> </ul>
415.	Rmz Colic Drop	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Monograph of mentha avensis extract/oil is required</li> </ul>
416.	Ginko Rite Forte Syrup	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
417.	Tri-Malt Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Stability studies undertaking is required</li> </ul>
418.	Maltobex M Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Stability studies undertaking is required</li> <li>• Brand name needs to be changed</li> </ul>

S.No (1)	Brand name (2)	Decision (3)
419.	Three Plex Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
420.	Dyra-Zole M Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
421.	Cofnex Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> </ul>
422.	Dyro-Nex Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Firm uses herbs in crude form</li> <li>• Confirmation/proof of herbal syrup section</li> </ul>
423.	Gestrozym Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• The applied formulation contains sodium bicarbonate which is in list of common molecule and deferred till the finalization of policy decision regarding common molecule</li> <li>• Properly filled signed and stamped form 3 is required</li> </ul>
424.	Z-Berry Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Properly filled signed and stamped form 3 is required</li> </ul>
425.	Dr. Cough Zee Dm Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Firm uses herbs in crude form</li> <li>• Confirmation of herbal syrup section</li> </ul>
426.	Mitfol Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Properly filled signed and stamped form 3 is required</li> </ul>
427.	Leucodil Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Firm uses herbs in crude form</li> <li>• Confirmation of herbal tablet section</li> <li>• Brand name needs to be changed</li> <li>• Properly filled signed and stamped form 3 is required</li> </ul>
<p align="center"><b>M/s MR Enterprises,</b>  <b>A-78/1 Shahbaz Town Scheme near Honda Place, Jamshoro Road, Qasimabad Hyderabad</b>  <b>agent of M/s Shandong Soocom Animal Remedy Co., Ltd., Xundakang Road No.666 agricultural high &amp; new technology</b>  <b>development zone of Jinan, China (Veterinary)</b></p>		
428.	Multivita WSP	Deferred for following reasons:



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• COA of active ingredient and finished product is required.</li> <li>• Long term stability studies data according to Zone IV-A requirement, mentioning percentage assay of each active ingredient is required.</li> <li>• Solo Agency agreement between principal manufacturer and importer i.e. M/s MR Enterprises is required.</li> </ul>
429.	Livercare Oral Solution	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Long term stability studies data according to Zone IV-A requirement, mentioning percentage assay of active ingredient e.g. DL –Methionine and L-Lysine is required.</li> <li>• COA of active ingredient and finished product is required.</li> <li>• Solo Agency agreement between principal manufacturer and importer i.e. M/s MR Enterprises is required.</li> </ul>
430.	VitE-SE10 Oral Solution	Deferred for following reasons: <ul style="list-style-type: none"> <li>• COA of active ingredient and finished product is required.</li> <li>• Solo Agency agreement between principal manufacturer and importer i.e. M/s MR Enterprises is required.</li> </ul>
<b>M/s Prospect Group (Pvt.) Ltd, 125-Upper Mall, Lahore agent of M/s Nutra Manufacturing, 1050 Woodruff Road, Greenville, SC 29607. Subsidiary of General Nutrition Corporation (GNC), USA (E. No. 00299)</b>		
431.	GNC (INTL) Double Strength Fish Oil Softgel Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC (INTL) Double Strength Fish Oil Softgel Capsule</li> <li>• and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Double Strength Fish Oil Softgel Capsule, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
432.	GNC Vit C 500 Rose Hips Caplets	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC Vit C 500 Rose Hips Caplets</li> <li>• and brand name given on Exhibit A attached copy of Certificate of Free Sale is Vit C 500 Rose Hips Caplets, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
433.	GNC Isomer E Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC Isomer E Capsule</li> <li>• Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is Isomer E Capsule, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
434.	GNC (INTL) Prima C 1000mg Tablet	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC (INTL) Prima C 1000mg Tablet</li> <li>• Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Prima C 1000mg Tablet, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
435.	GNC (INTL) Ginkgo Biloba Plus Tablet	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC (INTL) Ginkgo Biloba Plus Tablet</li> <li>• Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Ginkgo Biloba Plus Tablet, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
436.	GNC Kids Eye Health Chewable Tablet	Deferred for following reasons:



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC Kids Eye Health Chewable Tablet</li> <li>• Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is Kids Eye Health Chewable Tablet, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
437.	GNC Brighten Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC Brighten Capsule and brand name given on COA is Skin lightening Pil Vegetable Hard-shell capsule, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> <li>• Valid and Notarized free sale certificate attested by the regulatory body in the country of origin and countersigned by the Embassy of Pakistan in the country of origin</li> </ul>
438.	GNC (INTL) DHA 600 Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC (INTL) DHA 600 Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is Intl DHA 600, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
439.	GHC Ultra Saw Palmetto Formula Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GHC Ultra Saw Palmetto Formula Capsule</li> <li>• and brand name given on Exhibit A attached copy of Certificate of Free Sale is Ultra Saw Palmetto Formula Capsule, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
440.	GNC (INTL) Bitter Melon Extract Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC (INTL) Bitter Melon Extract Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Bitter Melon Extract Capsule, needs clarification.</li> </ul>
441.	GNC Senna Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC Senna Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is Senna Capsule, needs clarification.</li> </ul>
442.	GNC COQ-10 200 Softgel Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC COQ-10 200 Softgel Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is COQ-10 200 Softgel Capsule, needs clarification.</li> </ul>
443.	GNC Kids Multivitamin Chewable Tablet	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC Kids Multivitamin Chewable Tablet and brand name given on Exhibit A attached copy of Certificate of Free Sale is Kids Multivitamin Chewable Tablet, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
444.	GNC Valerian HP Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC Valerian HP Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is Valerian HP Capsule , needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
445.	GNC (INTL) COD Liver Oil Softgel capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC (INTL) COD Liver Oil Softgel capsule and brand name given on Exhibit A attached</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		copy of Certificate of Free Sale is INTL COD Liver Oil, needs clarification. <ul style="list-style-type: none"> <li>Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
446.	GNC PN Stress Support Caplets	Deferred for following reasons: <ul style="list-style-type: none"> <li>Brand Name mentioned on Form 5 is GNC PN Stress Support Caplets and brand name given on Exhibit A attached copy of Certificate of Free Sale is PN Stress Support Caplets, needs clarification.</li> <li>Monograph of Magnolia Bark Extract and Phellodendron Bark Extract are required.</li> <li>Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
447.	GNC Iron Complete Womens Caplets	Deferred for following reasons: <ul style="list-style-type: none"> <li>Brand Name mentioned on Form 5 is GNC Iron Complete Womens Caplets and brand name given on Exhibit A attached copy of Certificate of Free Sale is Iron Complete Womens Caplets, needs clarification.</li> <li>Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
448.	GNC Inositol 500 Tablet	Deferred for following reasons: <ul style="list-style-type: none"> <li>Brand Name mentioned on Form 5 is GNC Inositol 500 Tablet and brand name given on Exhibit A attached copy of Certificate of Free Sale is Inositol 500 Tablet, needs clarification.</li> <li>Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
449.	GNC (INTL) Mega Men 50 Plus Caplet	Deferred for following reasons: <ul style="list-style-type: none"> <li>Brand Name mentioned on Form 5 is GNC (INTL) Mega Men 50 Plus Caplet and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Mega Men 50 Plus Caplet, needs clarification.</li> <li>Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
450.	GNC (INTL) Wum 50+ Tablet	Deferred for following reasons: <ul style="list-style-type: none"> <li>Brand Name mentioned on Form 5 is GNC (INTL) Wum 50+ Tablet and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Wum 50+ Tablet, needs clarification.</li> <li>Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
451.	GNC Men's Arginmax Caplets	Deferred for following reasons: <ul style="list-style-type: none"> <li>Brand Name mentioned on Form 5 is GNC Men's Arginmax Caplets and brand name given on Exhibit A attached copy of Certificate of Free Sale is Men's Arginmax Caplets, needs clarification.</li> <li>Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
452.	GNC (INTL) Wum Essentials Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>Brand Name mentioned on Form 5 is GNC (INTL) Wum Essentials Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Wum Essentials Capsule, needs clarification.</li> <li>Long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
453.	GNC (INTL) AMP GOLD Thermo Tablet	Deferred for following reasons: <ul style="list-style-type: none"> <li>Brand Name mentioned on Form 5 is GNC (INTL) AMP GOLD Thermo Tablet and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL AMP GOLD Thermo Tablet, needs clarification.</li> </ul>



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> <li>Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> </ul>
<b>M/s Diversified Marketing Group (DMG), House # 245, Ground Floor, Saidpur Road, Scheme # 1, Rawalpindi agent of M/s Norel S.A., Pol.Ind.de Valls, Ctra. Pla Santa Maria, 271-273 43800. Valls (Tarragona), Spain (E. No. 00989)</b>		
454.	Anilox PSE-5	Deferred for following reasons: <ul style="list-style-type: none"> <li>Applied formulation is antioxidant, therefore role of this formulation under SRO 412 is required.</li> <li>Long term and accelerated stability studies data according to the requirements of Zone IV A are required.</li> </ul>
455.	Glymet Mix Plus	Deferred for following reasons: <ul style="list-style-type: none"> <li>Conversion of percentage strength into unit strength is required.</li> <li>Long term and accelerated stability studies data according to the requirements of Zone IV A are required.</li> </ul>
<b>M/s Getz Health (Pvt) Ltd, 29-30 Sector-27, Korangi Industrial Area, Karachi agent of M/s North China Pharmaceutical Hebei Huanuo Co., Ltd., No. 108, Haithe Road, Shijiazhuang High-Tech Zone, Hebei Province, China (E. No. 01133)</b>		
456.	Livity Nutritional Powder (Vanilla Flavour)	Deferred for following reasons: <ul style="list-style-type: none"> <li>Valid and notarized free sale certificate attested by the regulatory body in country of origin and countersigned by Embassy of Pakistan in country of Origin is required.</li> </ul>
<b>M/s ZS Biotech, 50-C Madina Block Awan Town Multan Road, Lahore-Pakistan agent of M/s Beijing Strowin Biology Science and Technology Co., Ltd., Rm. 1411, 14th floor of No.2 building, 1st Place, Shangdi 10th Road, Haidian District, Beijing. [(Site: No.5 Chenma Road), 1000m to the East Jianggezhuang village, Mulin town, Shunyi District, Beijing] (Veterinary) (E. No. 00484)</b>		
457.	Strogo D	Deferred for following reasons: <ul style="list-style-type: none"> <li>Role of Glucose Oxidase under SRO 412 is required.</li> <li>Long term and accelerated stability studies data according to requirements of Zone IV A is required.</li> <li>Valid and notarized free sale certificate attested by regulatory body in the country of origin and countersigned by Embassy of Pakistan in country of Origin.</li> </ul>
<b>M/s Metier Wellness Private Limited, 20, Sector 27, Korangi Industrial Area, Karachi-Pakistan agent of M/s Pharmalink S.L., Avinguda Universital Autonomia, 13, 08290, Cerdanyola del Valles, Barc-elona-Spain (E. No. 00721)</b>		
458.	Easy Sleep Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>Melatonin is included in the list of common molecule.</li> <li>Long term and accelerated stability studies data indicating physical, chemical and microbiological assay are required.</li> <li>Monograph of GABA and its role as health product under SRO 412 is required.</li> <li>Brand Name mentioned on Free sale certificate, COA and Stability Studies data is Eficaps Sueno while brand name on form 5 is Easy Sleep capsule, needs clarification in this regards.</li> </ul>
<b>M/s PDH Laboratories Pvt. Ltd., Near Dosaco Chowk, 9.5-Km Sheikhpura Road, District Sheikhpura agent of M/s PT Novell Pharmaceutical Laboratories, located at Jalan Wanaherang No.35, Tlajung Udik, Gunung Putri City, Bogor Province, West Java, Indonesia (E.No. 01115)</b>		
459.	Lithotrip Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>Monograph of oleum lini, Oleum Janiperi and Oleum Menthae Piperitae are required.</li> <li>Long term and accelerated stability studies indicating chemical assay of active ingredients is required.</li> <li>Valid and Notarized Free sale certificate attested by regulatory body in country of origin and countersigned by the Embassy of Pakistan in country of origin.</li> </ul>
<b>M/s Huzaifa International, Commercial Area, Aziz Bhatti Town, Sargodha agent of M/s Shandong Soocom Animal Remedy Co., Ltd., Xundakang Road No. 666 Agricultural High &amp; New Technology Development Zone of Jinan, China (E. No. 01084)</b>		



S.No (1)	Brand name (2)	Decision (3)
460.	Soocom-Acid Oral Solution	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Signed and Stamped Form 5 under SRO 412 is required.</li> <li>• Evidence is required either Shondong Animal Husbandry and veterinary Bureau is authorized regulatory body itself or as been authorized by Government of China as a third party to issue free sale certificate.</li> </ul>
<b>M/s Nutri Tech, 55-C,                      Malik Naeem Street, Aitchison Society, Raiwind Road, Lahore                      agent of M/s Kemin Europa N.V, Toekomstlaan 42, 2200 Herentals, Belgium (Principal manufacturer: M/s Kemin Cavriago SRL, Via Nizzola 5, 42025 – Cavriago (RE) Italy) (E. No. 00986)</b>		
461.	LysiPearl	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Signed and stamped form 5 is required.</li> <li>• Conversion of percentage strength into unit strength is required and per serving dose is also required.</li> <li>• Long term (according to Zone IV A) and accelerated stability studies data indicating physical and microbiological assay are required.</li> <li>• Valid Free sale certificate to be attested by concern regulatory body in the country of origin, notarized and countersigned by Embassy of Pakistan in country of Origin.</li> </ul>
462.	ButiPeral	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Signed and stamped form 5 is required.</li> <li>• Conversion of percentage strength into unit strength is required and per serving dose is also required.</li> <li>• Role of calcium butyrate under SRO 412 is required.</li> <li>• Long term (according to Zone IV A) and accelerated stability studies data indicating physical and microbiological assay are required.</li> <li>• Valid Free sale certificate to be attested by concern regulatory body in the country of origin, notarized and countersigned by Embassy of Pakistan in country of Origin.</li> </ul>
463.	LysiGem	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Signed and stamped form 5 is required.</li> <li>• Long term (according to Zone IV A) and accelerated stability studies data indicating physical and microbiological assay are required.</li> <li>• Furthermore long term stability studies data should be given after every 3 months in first year, every six months in second year and every year thereafter.</li> <li>• Valid Free sale certificate to be attested by concern regulatory body in the country of origin notarized and countersigned by Embassy of Pakistan in country of Origin.</li> </ul>
464.	CholiPeral	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Signed and stamped form 5 is required.</li> <li>• Conversion of percentage strength into unit strength is required and per serving dose is also required.</li> <li>• Long term (according to Zone IV A) and accelerated stability studies data indicating physical and microbiological assay are required.</li> <li>• Valid Free sale certificate to be attested by concern regulatory body in the country of origin, notarized and countersigned by Embassy of Pakistan in country of Origin.</li> </ul>
465.	NutriCab	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Signed and stamped form 5 is required.</li> <li>• Justification of Formulation is required.</li> <li>• Conversion of percentage strength into unit strength is required and per serving dose is also required.</li> <li>• required.</li> </ul>





S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Long term (according to Zone IV A) and accelerated stability studies data indicating physical and microbiological assay are required.</li> <li>• Furthermore long term stability studies data should be given after every 3 months in first year, every six months in second year and every year thereafter.</li> <li>• Valid Free sale certificate to be attested by concern regulatory body in the country of origin, notarized and countersigned by Embassy of Pakistan in country of Origin.</li> </ul>
466.	MetiPearl	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Signed and stamped form 5 is required.</li> <li>• Conversion of percentage strength into unit strength is required and per serving dose is also required.</li> <li>• Long term (according to Zone IV A) and accelerated stability studies data indicating physical and microbiological assay are required.</li> <li>• Valid Free sale certificate to be attested by concern regulatory body in the country of origin, notarized and countersigned by Embassy of Pakistan in country of Origin.</li> </ul>
<p align="center"><b>M/s Jacked Nutrition, Shop No. 2 and 3, Ground Floor, Commercial Plot No. 1, Multi Arcade, E-11/1, Islamabad agent of M/s Blade Sport Kft. HU 1055 Budapest, Nyugati square 6, Hungary (Principal Manufacturer M/s Elelmiszteripari Kft., Pinkeret 1, H-9142, Rabapatona, Hungary) (E. No. 01083)</b></p>		
467.	BLADE Casein (CHOCOLATE) 1816g	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Hilal source certificate of Fats and protein are required.</li> <li>• Strength of Whey protein concentrate is required.</li> <li>• Sub type of Protein along with strength is required.</li> <li>• Copy of free sale certificate issued by Food Chain Safety and land registry department of the government depicts the name of producer of the said product but does not provided any information about market rights holder i.e M/s Blade Sports , Hungry.</li> <li>• COA of Finished product is required.</li> <li>• Long term and accelerated Stability studies data according to Zone IV A is required.</li> <li>• Valid GMP certificate is required.</li> <li>• Strength of protein matrix and casein concentrate is required.</li> </ul>
468.	BLADE Muscle maxx (CHOCOLATE)	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Hilal source certificate of Fats and protein are required.</li> <li>• Strength of Whey protein concentrate is required.</li> <li>• Sub type of Protein along with strength is required.</li> <li>• Copy of free sale certificate issued by Food Chain Safety and land registry department of the government depicts the name of producer of the said product but does not provided any information about market rights holder i.e. M/s Blade Sports , Hungry.</li> <li>• COA of Finished product is required.</li> <li>• Long term and accelerated Stability studies data according to Zone IV A is required.</li> <li>• Valid GMP certificate is required.</li> </ul>
469.	BLADE Protein Concentrate (CHOCOLATE)	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Hilal source certificate of Fats and protein are required.</li> <li>• Strength of Whey protein concentrate is required.</li> <li>• Sub type of Protein along with strength is required.</li> <li>• Copy of free sale certificate issued by Food Chain Safety and land registry department of the government depicts the name of producer of the said product but does not provided any information about market rights holder i.e. M/s Blade Sports , Hungry.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• COA of Finished product is required.</li> <li>• Long term and accelerated Stability studies data according to Zone IV A is required.</li> <li>• Valid GMP certificate is required.</li> </ul>
470.	BLADE WHEY PROTEIN (CHOCOLATE)	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Hilal source certificate of Fats and protein are required.</li> <li>• Sub type of Protein along with strength is required.</li> <li>• Copy of free sale certificate issued by Food Chain Safety and land registry department of the government depicts the name of producer of the said product but does not provided any information about market rights holder i.e. M/s Blade Sports , Hungry.</li> <li>• COA of Finished product is required.</li> <li>• Long term and accelerated Stability studies data according to Zone IV A is required.</li> <li>• Valid GMP certificate is required.</li> </ul>
<p align="center"><b>M/s Edmark, Shop No. 29, Ground Floor, Noorani Medicine Market, North Napier Road, Karachi agent of M/s Edmark Industries SDN, BHD., No, Jalan BK 1/13, Kinrara Industries Park, 471800 Puchong, Selangor Darul Ehasn, Malaysia (E. No. 01142)</b></p>		
471.	Edmark's Hawaiian Spirulina Tablet (Chewable)	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient is required.</li> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
472.	Edmark's Bubble C Orange Drink Powder	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Role of Dextrose and Fructose as health product is required.</li> <li>• Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient is required.</li> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
473.	Edmark's Bio Elixir Powder	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Sub-types of Amino Acid, Vitamins and Minerals along their strength is required.</li> <li>• Long term and Accelerated stability Studies data indicating chemical assay of each active ingredient is required.</li> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
474.	Edmark's Cafe 73 Powder	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Role of formulation as health product is required.</li> <li>• Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient is required.</li> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
475.	Edmark's Edmark Cafe Ginseng Coffee Powder	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Role of sugar, Non Dairy Creamer, instant coffee powder as health product are required.</li> <li>• Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient is required.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
476.	Edmark's Edmark Cafe Powder Black Powder	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Role of formulation as health product is required.</li> <li>• Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient is required.</li> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
477.	Edmark's Edmark Cafe Troika Powder	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Role of sugar, Non Dairy Creamer, instant coffee powder as health product are required.</li> <li>• Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient is required.</li> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
478.	Edmark's Edmark Cocollagen Drink Powder	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Role of formulation as health product is required.</li> <li>• Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient is required.</li> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
479.	Edmark's Edmark Splina Liquid Chlorophyll	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Role of Chlorophyll Powder as health product are required.</li> <li>• Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient is required.</li> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
480.	Edmark's Edmark MRT Complex Powder	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Role of Low fat milk, chocolate powder and Fructose, Guar Gum as health product are required.</li> <li>• Sub type of Vitamin B Complex along with strength is required.</li> <li>• Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient is required.</li> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
481.	Edmark's Edmark Shake Off Phyto Fiber Powder	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Role of formulation as health product is required.</li> <li>• Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient is required.</li> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
482.	Edmark's Edmark Spiro Sachet	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Role of sugar, Non Dairy Creamer, instant coffee powder and brown rice as health product are required.</li> <li>• Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient is required.</li> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
483.	Edmark Mocha Powder	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Role of Sugar, Non Dairy Creamer, Skim Milk Powder and Cocoa Powder as health product is required.</li> <li>• Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient is required.</li> <li>• COA of finished product indicating chemical assay of each active ingredient is required.</li> <li>• Last inspection report attested by the regulatory body countersigned by Embassy of Pakistan in country of origin.</li> </ul>
<b>M/s Macter International Limited, F-216, SITE, Karachi agent of M/s Best Formulation INC. 17758 Rowland Street City of Industry CA 91748, USA</b>		
484.	MAC CBD	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Long term and accelerated stability studies data according to requirements of Zone IV A are required.</li> <li>• Valid and notarized Free sale certificate attested by the regulatory body in the country of origin and countersigned by the Embassy of Pakistan in the country of origin is required.</li> <li>• It is stated that cannabidiol in the strength of 100mg/ml is registered as a drug in exporting country (USA), in this regards clarification is required w.r.t. cannabidiol oil as health product under SRO 412.</li> <li>• Agency agreement between principal manufacturer i.e. M/s Best Formulation, USA and M/s Macter International, Karachi is required. As one document on the subject "Distributorship, Regulatory, Sales and Marketing agreement" is between M/s Green Releaf LLC, NY, USA and M/s Macter International, Karachi. In this regards, this information is not depicted in form 6.</li> </ul>
485.	MAC CBD	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Long term and accelerated stability studies data according to requirements of Zone IV A are required.</li> <li>• Valid and notarized Free sale certificate attested by the regulatory body in the country of origin and countersigned by the Embassy of Pakistan in the country of origin is required.</li> <li>• It is stated that cannabidiol in the strength of 100mg/ml is registered as a drug in exporting country (USA), in this regards clarification is required w.r.t. cannabidiol oil as health product under SRO 412.</li> <li>• Agency agreement between principal manufacturer i.e. M/s Best Formulation, USA and M/s Macter International, Karachi is required. As one document on the subject "Distributorship, Regulatory, Sales and Marketing agreement" is between M/s Green Releaf LLC, NY, USA and M/s Macter International, Karachi. In this regards, this information is not depicted in form 6.</li> </ul>
486.	MAC CBD	Deferred for following reasons:



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Long term and accelerated stability studies data according to requirements of Zone IV A are required.</li> <li>• Valid and notarized Free sale certificate attested by the regulatory body in the country of origin and countersigned by the Embassy of Pakistan in the country of origin is required.</li> <li>• It is stated that cannabidiol in the strength of 100mg /ml is registered as a drug in exporting country (USA), in this regards clarification is required w.r.t. cannabidiol oil as health product under SRO 412.</li> <li>• Agency agreement between principal manufacturer i.e. M/s Best Formulation, USA and M/s Macter International, Karachi is required. As one document on the subject "Distributorship, Regulatory, Sales and Marketing agreement" is between M/s Green Releaf LLC, NY, USA and M/s Macter International, Karachi. In this regards, this information is not depicted in form 6.</li> </ul>
<b>M/s SHS Nutrition, Shireen Arcade, Mezzanine Floor, Suite No. 3, Plot No. A-41, K.C.H.S.U Block 7/8 Karachi agent of M/s Shanghai QiangSheng Wanshineng Health Co. Ltd. No. 315 Fengparo Rd, Haiwan Toursim, Fengxin Town, Fengxian District, Shanghai, China (E. No. 0058)</b>		
487.	ActiLife F 50+ Tablet	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Accelerated stability Studies data is required.</li> <li>• Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.</li> <li>• Agency agreement letter issued by Shanghai VitaOn Biotechnologies Co. Ltd., China states that M/s <b>Shanghai QiangSheng Wanshineng Health Co. Ltd. China has been contracted by M/s Shanghai VitaOn Biotechnologies Co. Ltd., China to Manufacture the said product, while M/s Shanghai VitaOn Biotechnologies Co. Ltd., China remains the sole owner of product. In this regards clarification is required w.r.t manufacturer and marketing authorization rights of the said product as no such information is available on Form 6..</b></li> </ul>
488.	Pregnable F Tablet	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Accelerated stability Studies data is required.</li> <li>• Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.</li> <li>• Agency agreement letter issued by Shanghai VitaOn Biotechnologies Co. Ltd., China states that M/s <b>Shanghai QiangSheng Wanshineng Health Co. Ltd. China has been contracted by M/s Shanghai VitaOn Biotechnologies Co. Ltd., China to Manufacture the said product, while M/s Shanghai VitaOn Biotechnologies Co. Ltd., China remains the sole owner of product. In this regards clarification is required w.r.t manufacturer and marketing authorization rights of the said product as no such information is available on Form 6..</b></li> </ul>
489.	Acti-Joint Tablet	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Glucosamine and Chondroitin Sulpahte are included in list of common molecule.</li> <li>• Accelerated stability Studies data is required.</li> <li>• Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.</li> <li>• Agency agreement letter issued by Shanghai VitaOn Biotechnologies Co. Ltd., China states that M/s <b>Shanghai QiangSheng Wanshineng Health Co. Ltd. China has been contracted by M/s Shanghai VitaOn Biotechnologies Co. Ltd.,</b></li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		China to Manufacture the said product, while M/s Shanghai VitaOn Biotechnologies Co. Ltd., China remains the sole owner of product. In this regards clarification is required w.r.t manufacturer and marketing authorization rights of the said product as no such information is available on Form 6.
490.	Pregnable M Tablet	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Accelerated stability Studies data is required.</li> <li>• Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.</li> <li>• Agency agreement letter issued by Shanghai VitaOn Biotechnologies Co. Ltd., China states that M/s <b>Shanghai QiangSheng Wanshineng Health Co. Ltd. China has been contracted by M/s Shanghai VitaOn Biotechnologies Co. Ltd.,</b> China to Manufacture the said product, while M/s Shanghai VitaOn Biotechnologies Co. Ltd., China remains the sole owner of product. In this regards clarification is required w.r.t manufacturer and marketing authorization rights of the said product as no such information is available on Form 6.</li> </ul>
491.	Bonnicare Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Accelerated stability Studies data is required.</li> <li>• Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.</li> <li>• Agency agreement letter issued by Shanghai VitaOn Biotechnologies Co. Ltd., China states that M/s <b>Shanghai QiangSheng Wanshineng Health Co. Ltd. China has been contracted by M/s Shanghai VitaOn Biotechnologies Co. Ltd.,</b> China to Manufacture the said product, while M/s Shanghai VitaOn Biotechnologies Co. Ltd., China remains the sole owner of product. In this regards clarification is required w.r.t manufacturer and marketing authorization rights of the said product as no such information is available on Form 6.</li> <li>• Firm applied fee challan of Rs. 2000 for bonnicare capsule and tablet, wherein form 5 contains composition of both capsule and tablet as dosage form, needs following points/clarification:</li> <li>• Separate fee is required for each dosage form for enlistment.</li> <li>• Stability studies data long term and accelerated of bonnicare tablet is also required.</li> </ul>
492.	Stimulin Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Accelerated stability Studies data is required.</li> <li>• Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.</li> <li>• Agency agreement letter issued by Shanghai VitaOn Biotechnologies Co. Ltd., China states that M/s <b>Shanghai QiangSheng Wanshineng Health Co. Ltd. China has been contracted by M/s Shanghai VitaOn Biotechnologies Co. Ltd.,</b> China to Manufacture the said product, while M/s Shanghai VitaOn Biotechnologies Co. Ltd., China remains the sole owner of product. In this regards clarification is required w.r.t manufacturer and marketing authorization rights of the said product as no such information is available on Form 6.</li> </ul>
493.	Bonetabl Tablet	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Accelerated stability Studies data is required.</li> <li>• Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.</li> <li>• Agency agreement letter issued by Shanghai VitaOn Biotechnologies Co. Ltd., China states that M/s <b>Shanghai</b></li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<p><b>QiangSheng Wanshineng Health Co. Ltd. China has been contracted by M/s Shanghai VitaOn Biotechnologies Co. Ltd., China to Manufacture the said product, while M/s Shanghai VitaOn Biotechnologies Co. Ltd., China remains the sole owner of product. In this regards clarification is required w.r.t manufacturer and marketing authorization rights of the said product as no such information is available on Form 6.</b></p>
494.	Joggle Box Tablet	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Chitosammine and Chondroitin Sulphate is included in the list of common molecule.</li> <li>• Accelerated stability Studies data is required.</li> <li>• Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.</li> <li>• Agency agreement letter issued by Shanghai VitaOn Biotechnologies Co. Ltd., China states that M/s <b>Shanghai QiangSheng Wanshineng Health Co. Ltd. China has been contracted by M/s Shanghai VitaOn Biotechnologies Co. Ltd., China to Manufacture the said product, while M/s Shanghai VitaOn Biotechnologies Co. Ltd., China remains the sole owner of product. In this regards clarification is required w.r.t manufacturer and marketing authorization rights of the said product as no such information is available on Form 6.</b></li> <li>• Justification is required w.r.t Chitosammine as an active ingredient.</li> </ul>
495.	ActiLife F Capsule	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Accelerated stability Studies data is required.</li> <li>• Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.</li> <li>• Agency agreement letter issued by Shanghai VitaOn Biotechnologies Co. Ltd., China states that M/s <b>Shanghai QiangSheng Wanshineng Health Co. Ltd. China has been contracted by M/s Shanghai VitaOn Biotechnologies Co. Ltd., China to Manufacture the said product, while M/s Shanghai VitaOn Biotechnologies Co. Ltd., China remains the sole owner of product. In this regards clarification is required w.r.t manufacturer and marketing authorization rights of the said product as no such information is available on Form 6.</b></li> </ul>
496.	Actifile M capsule	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Form 5 is required to be revised w.r.t justification either active ingredient are contains in one capsule oor 2 capsules.</li> <li>• Long term and Accelerated stability Studies data is required as per requirement of Zone IV A is required..</li> <li>• Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.</li> <li>• Agency agreement letter issued by Shanghai VitaOn Biotechnologies Co. Ltd., China states that M/s <b>Shanghai QiangSheng Wanshineng Health Co. Ltd. China has been contracted by M/s Shanghai VitaOn Biotechnologies Co. Ltd., China to Manufacture the said product, while M/s Shanghai VitaOn Biotechnologies Co. Ltd., China remains the sole owner of product. In this regards clarification is required w.r.t manufacturer and marketing authorization rights of the said product as no such information is available on Form 6.</b></li> <li>• COA of active ingredient and finished product is required.</li> </ul>
497.	Actilife M50+ Tablet	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>• Form 5 is required to be revised w.r.t justification either active ingredient are contains in one Tablet or 2 Tablets.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Accelerated stability Studies data is required.</li> <li>Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.</li> <li>Agency agreement letter issued by Shanghai VitaOn Biotechnologies Co. Ltd., China states that <b>M/s Shanghai QiangSheng Wanshineng Health Co. Ltd. China has been contracted by M/s Shanghai VitaOn Biotechnologies Co. Ltd., China to Manufacture the said product, while M/s Shanghai VitaOn Biotechnologies Co. Ltd., China remains the sole owner of product. In this regards clarification is required w.r.t manufacturer and marketing authorization rights of the said product as no such information is available on Form 6..</b></li> </ul>
498.	Proganycare Capsule	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>Long term and Accelerated stability Studies data according to Zone IV A is required.</li> <li>Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.</li> <li>Agency agreement letter issued by Shanghai VitaOn Biotechnologies Co. Ltd., China states that <b>M/s Shanghai QiangSheng Wanshineng Health Co. Ltd. China has been contracted by M/s Shanghai VitaOn Biotechnologies Co. Ltd., China to Manufacture the said product, while M/s Shanghai VitaOn Biotechnologies Co. Ltd., China remains the sole owner of product. In this regards clarification is required w.r.t manufacturer and marketing authorization rights of the said product as no such information is available on Form 6.</b></li> <li>COA of active ingredients and finished product is required.</li> </ul>
<p><b>M/s Suas Pharmaceuticals., Suite 338, 3rd Floor, Land Mark Plaza, 5/6 Jail Road, Lahore agent of M/s Natural Fervor Inc., 17801-J Sky Park Circle, Irvine, CA 92614 USA (Principal Manufacturer: M/s Viva Pharmaceutical Inc., 13880 Viking Place, Richmond, British Columbia, Canada) (E. No. 01144)</b></p>		
499.	Multivitamin Gummy	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>Signed and stamped Form 5 under SRO 412 is required.</li> <li>Long term and Accelerated stability studies data according to requirements of Zone IV A are required.</li> <li>Valid and notarized free sale certificate attested by the regulatory body in country of origin and countersigned by Embassy of Pakistan in country of Origin.</li> </ul>
500.	Antioxidant Gummy	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>Signed and stamped Form 5 under SRO 412 is required.</li> <li>Long term and Accelerated stability studies data according to requirements of Zone IV A are required.</li> <li>Valid and notarized free sale certificate attested by the regulatory body in country of origin and countersigned by Embassy of Pakistan in country of Origin.</li> </ul>
501.	Stronger Bones	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>Signed and stamped Form 5 under SRO 412 is required.</li> <li>Long term and Accelerated stability studies data according to requirements of Zone IV A are required.</li> <li>Valid and notarized free sale certificate attested by the regulatory body in country of origin and countersigned by Embassy of Pakistan in country of Origin.</li> </ul>
<p><b>M/s Peshawar Traders (Pvt) Ltd., 2-5 Mulagori Plaza Bacha Khan Chowak Peshawar agent of M/s Biovet, S.A., C/Luxemburg, 25 Poligon Industrial, 43120 Constanti – Tarragona, Spain (E. No. 00882)</b></p>		
502.	Alquerfeed Esevital	<p>Deferred for following reasons:</p> <ul style="list-style-type: none"> <li>Application to be applied on prescribed form 5 under SRO 412(I)/2014.</li> </ul>





S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Accelerated and long term stability studies data indicating physical assay and microbiological assay are required.</li> </ul>
503.	Alquernat Livol L	Deferred for following reasons: <ul style="list-style-type: none"> <li>Application to be applied on prescribed form 5 under SRO 412(I)/2014.</li> <li>Accelerated and long term stability studies data indicating physical assay and microbiological assay are required.</li> </ul>
504.	Alqueplus Revital	Deferred for following reasons: <ul style="list-style-type: none"> <li>Application to be applied on prescribed form 5 under SRO 412(I)/2014.</li> <li>Accelerated and long term stability studies data indicating physical assay and microbiological assay are required.</li> <li>Formulation contains Glucose as an active ingredient, which is included in the list of common molecule.</li> </ul>
505.	Alquernat Zycox L	Deferred for following reasons: <ul style="list-style-type: none"> <li>Application to be applied on prescribed form 5 under SRO 412(I)/2014.</li> <li>Accelerated and long term stability studies data indicating physical assay and microbiological assay are required.</li> </ul>
506.	Alquermold Natural L	Deferred for following reasons: <ul style="list-style-type: none"> <li>Application to be applied on prescribed form 5 under SRO 412(I)/2014.</li> <li>Accelerated and long term stability studies data indicating physical assay and microbiological assay are required.</li> </ul>
<b>M/s Genetics Healthcare, 537-A, Sundar Industrial Estate, Lahore agent of M/s BioGrowing Co. Ltd. No. 10666, Songze Rd, Qingpu, Shanghai, 201700, CHINA (E. No. 00103)</b>		
507.	Ezegut capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>Form 5 to be revised w.r.t strength (enumeration) of each probiotic according to strength given in master formula.</li> <li>COA of finished product indicating assay of each probiotic (mentioned in formulation) is required.</li> <li>Testing specification and characterization of each probiotic is required.</li> <li>Valid and Notarized Free sale certificate attested by the regulatory body and countersigned by the Embassy of Pakistan in country of origin.</li> <li>Long term and accelerated stability studies data according to requirement of Zone IV A is are required.</li> <li>Pack size is not provided.</li> </ul>
508.	Heligut Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>Form 5 to be revised w.r.t strength (enumeration) of each probiotic according to strength given in master formula.</li> <li>COA of finished product indicating assay of each probiotics (mentioned in formulation) is required.</li> <li>Testing specification and characterization of each probiotics is required.</li> <li>Valid and Notarized Free sale certificate attested by the regulatory body and countersigned by the Embassy of Pakistan in country of origin.</li> <li>Long term and accelerated stability studies data according to requirement of Zone IV A is are required.</li> <li>Pack size is not provided.</li> </ul>
509.	Biolip Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>Form 5 to be revised w.r.t strength (enumeration) of each probiotics according to strength given in master formula.</li> <li>COA of finished product indicating assay of each probiotics (mentioned in formulation) is required.</li> </ul>

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Testing specification and characterization of each probiotics is required.</li> <li>• Valid and Notarized Free sale certificate attested by the regulatory body and countersigned by the Embassy of Pakistan in country of origin.</li> <li>• Long term and accelerated stability studies data according to requirement of Zone IV A is are required.</li> <li>• Pack size is not provided.</li> </ul>
510.	Grab Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Form 5 to be revised w.r.t strength (enumeration) of each probiotic according to strength given in master formula.</li> <li>• COA of finished product indicating assay of each probiotic (mentioned in formulation) is required.</li> <li>• Specific stain of each probiotics is required.</li> <li>• Testing specification and characterization of each probiotic is required.</li> <li>• Monograph of GABA and its roles as health product under SRO 412 is required.</li> <li>• Valid and Notarized Free sale certificate attested by the regulatory body and countersigned by the Embassy of Pakistan in country of origin.</li> <li>• Long term and accelerated stability studies data according to requirement of Zone IV A is are required.</li> <li>• Pack size is not provided.</li> </ul>
511.	Sinohale Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Form 5 to be revised w.r.t strength (enumeration) of each probiotic according to strength given in master formula.</li> <li>• COA of finished product indicating assay of each probiotic (mentioned in formulation) is required.</li> <li>• Testing specification and characterization of each probiotic is required.</li> <li>• Valid and Notarized Free sale certificate attested by the regulatory body and countersigned by the Embassy of Pakistan in country of origin.</li> <li>• Long term and accelerated stability studies data according to requirement of Zone IV A is are required.</li> <li>• Pack size is not provided.</li> </ul>
<b>M/s Schazoo SPL Consumer Healthcare, 71-B, C/2, Gulberg III, Lahore agent of M/s S.I.I.T S.R.L Servizio Internazionale Imballaggi Termosaldanti, Via L. Ariosto, 50/60-20090 Sul Naviglio, Italy (E. No. 00948)</b>		
512.	Duravit Pregnancy Tablet	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Brand Name needs to be changed and alternate brand name (s) to be provided by principal manufacturer on its company's/firm's letter head.</li> <li>• Long term stability studies data according to requirement of Zone IV A.</li> </ul>
<b>M/s Tec Man International,, House No. 226, Race Course Road, Westridge No. 1 Rawalpindi agent of M/s Bedson S.A, Las Palmeras 2240, Ruta 8-Km, 47 (1629) La Lonja, Pilar, Buenos Aires, Argentina (E. No. 01029)</b>		
513.	Bedgen 40 SFA concentrate	Deferred for following reasons: <ul style="list-style-type: none"> <li>• COA of active ingredient and Finished product.</li> <li>• Accelerated and long term stability studies data according to requirement of Zone IV A.</li> <li>• Free Sale Certificate is required.</li> <li>• GMP Certificate is required.</li> </ul>
<b>M/s Metier Wellness Private Limited, 20 Sector 27, Korangi Industrial Area, Karachi agent of M/s HC Clover Productos Y Servicios, S.L C/Alicante, 8-10 Arganda del Rey, 28500, Madrid, Spain (E. No. 01049)</b>		



S.No (1)	Brand name (2)	Decision (3)
514.	Super Krill Softgel Capsules	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Monograph of Pure Krill Oil is required.</li> <li>• Long term and accelerated stability studies indicating chemical assay of active ingredient, according to requirements of Zone IV A is required.</li> </ul>
515.	Prima Cap Softgel Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Strength of active ingredients mention on form 5 and a letter issued by Directorate General of Public Health, Hereby are not identical, needs clarification in this regards.</li> </ul>
516.	Cod Oil Softgel Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Strength of ingredients mentioned on form 5 and document issued by Directorate General of Public Health Hereby, Spain are different, needs clarification in this regards.</li> </ul>
517.	Char Clean Softgel Capsule	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Charcoal is included in the list of common molecule.</li> </ul>
<p align="center"><b>M/s Ghazi Brothers,</b>  <b>Ghazi House, D-35, KDA Scheme #1, Miran Muhammad Shah Road, Karachi-75350-Pakistan</b>  <b>agent of M/s Crown Pacific Biotechnology Pte. Ltd. 38 Penjuru Lane, Singapore 609204 (Veterinary) (E. No. 00720)</b></p>		
518.	GB Vitalink Feed Grade	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Long term and accelerated stability studies data according to the requirements of Zone IV A are required.</li> </ul>
519.	GB Nutrimin Feed Grade	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Long term and accelerated stability studies data according to the requirements of Zone IV A are required.</li> </ul>
<p align="center"><b>M/s Galaxy Pharma (Pvt) Limited,</b>  <b>D-180, Rojhan Street, Block-5, Clifton, Karachi-75600</b>  <b>agent of M/s Lo. Li Pharma International, Roma-00156-VIA dei LUXARDO, 33-VAT.067851002, Italy (E. No. 0056)</b></p>		
520.	Alfagut Pakistan	Deferred for following reasons: <ul style="list-style-type: none"> <li>• COA of active ingredients and finished product is required.</li> <li>• Monograph of Alfa-Lactalbumin is required.</li> <li>• Role of Alfa Lactalbumin as health product under SRO 412 is required.</li> <li>• Valid and Notarized Free sale certificate attested by the regulatory body and countersigned by the Embassy of Pakistan in country of origin.</li> <li>• Long term and accelerated stability studies data according to requirement of Zone IV A is are required.</li> <li>• Pack size is not provided.</li> </ul>

  
(Ayyaz Ahmad)

**Secretary, Enlistment Evaluation Committee**

# ANNEXURE

The firm is directed to submit soft data in both MS Excel & MS Word on following formats in **USB ONLY.**

## MS Excel Format

Sr. No.	Company name	Product Name	Dosage Form	Composition	Common name	Recommended use	Pack Size	Date of R&I submission
1.	(Company name, City)  Without address	XYZ	Tablet	Each tablet contains:  Abc (USP)...50mg	XXX	XXX	10's 20's	DD.MM.YYYY
2.								

## MS Word Format

Sr. No.	Company name	Product Name and composition	Common name	Recommended use	Pack Size
1.	(Company name, City)  Without address	XYZ Tablet  Each tablet contains: Abc (USP)....50mg	XXX	XXX	10's 20's
2.					